

Kent Academic Repository

Nutalai, Rungtiwa, Zhou, Daming, Tuekprakhon, Aekkachai, Ginn, Helen M., Supasa, Piyada, Liu, Chang, Huo, Jiandong, Mentzer, Alexander J., Duyvesteyn, Helen M.E., Dijokaite-Guraliuc, Aiste and others (2022) *Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.* Cell . ISSN 0092-8674.

Downloaded from https://kar.kent.ac.uk/95166/ The University of Kent's Academic Repository KAR

The version of record is available from https://doi.org/10.1016/j.cell.2022.05.014

This document version Author's Accepted Manuscript

DOI for this version

Licence for this version UNSPECIFIED

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts


If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact <u>ResearchSupport@kent.ac.uk</u>. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our <u>Take Down policy</u> (available from <u>https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies</u>).

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Rungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, Helen M. Ginn, Piyada Supasa, Chang Liu, Jiandong Huo, Alexander J. Mentzer, Helen M.E. Duyvesteyn, Aiste Dijokaite-Guraliuc, Donal Skelly, Thomas G. Ritter, Ali Amini, Sagida Bibi, Sandra Adele, Sile Ann Johnson, Bede Constantinides, Hermione Webster, Nigel Temperton, Paul Klenerman, Eleanor Barnes, Susanna J. Dunachie, Derrick Crook, Andrew J. Pollard, Teresa Lambe, Philip Goulder, OPTIC consortium, ISARIC4C consortium, Neil G. Paterson, Mark A. Williams, David R. Hall, Juthathip Mongkolsapaya, Elizabeth E. Fry, Wanwisa Dejnirattisai, Jingshan Ren, David I. Stuart, Gavin R. Screaton



PII: S0092-8674(22)00598-0

DOI: https://doi.org/10.1016/j.cell.2022.05.014

Reference: CELL 12487

To appear in: Cell

Received Date: 21 February 2022

Revised Date: 4 April 2022


Accepted Date: 14 May 2022

Please cite this article as: Nutalai, R., Zhou, D., Tuekprakhon, A., Ginn, H.M., Supasa, P., Liu, C., Huo, J., Mentzer, A.J., Duyvesteyn, H.M.E., Dijokaite-Guraliuc, A., Skelly, D., Ritter, T.G., Amini, A., Bibi, S., Adele, S., Johnson, S.A., Constantinides, B., Webster, H., Temperton, N., Klenerman, P., Barnes, E., Dunachie, S.J., Crook, D., Pollard, A.J, Lambe, T., Goulder, P., OPTIC consortium, ISARIC4C consortium, Paterson, N.G., Williams, M.A., Hall, D.R., Mongkolsapaya, J., Fry, E.E., Dejnirattisai, W., Ren, J., Stuart, D.I., Screaton, G.R, Potent cross-reactive antibodies following Omicron breakthrough in vaccinees, *Cell* (2022), doi: https://doi.org/10.1016/j.cell.2022.05.014.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that,

during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s). Published by Elsevier Inc.



27 potent RBD-binding mAbs isolated after Omicron-BA.1 infection following vaccine breakthrough are focussed in two main clusters within the RBD. Rightshoulder antibodies show increased prevalence. All potently neutralize early pandemic virus and many show broad reactivity with variants of concern.

	Journal Pre-proof
1 2 3	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
4	
5 6 7 8 9 10 11 12 13 14 15 16	Rungtiwa Nutalai ^{1,#} , Daming Zhou ^{2,3,#} , Aekkachai Tuekprakhon ^{1, #} , Helen M. Ginn ^{4,#} , Piyada Supasa ^{1,#} , Chang Liu ^{1,3,#} , Jiandong Huo ^{2,#} , Alexander J. Mentzer ^{1,5,#} , Helen M.E. Duyvesteyn ² , Aiste Dijokaite-Guraliuc ¹ , Donal Skelly ^{5,6,7} , Thomas G. Ritter ⁵ , Ali Amini ^{5,6,8} , Sagida Bibi ⁹ , Sandra Adele ⁵ , Sile Ann Johnson ⁵ , Bede Constantinides ¹⁰ , Hermione Webster ¹⁰ , Nigel Temperton ¹¹ , Paul Klenerman ^{5,6,8,12} , Eleanor Barnes ^{5,6,8,12} , Susanna J. Dunachie, ^{5,6,13,14} , Derrick Crook ¹⁰ , Andrew J Pollard ^{9,12} , Teresa Lambe ^{3,9} , Philip Goulder ^{6,15} , OPTIC consortium ^{&} , ISARIC4C consortium [§] , Neil G. Paterson ⁴ , Mark A. Williams ⁴ , David R. Hall ⁴ , Juthathip Mongkolsapaya ^{1,3} , Elizabeth E. Fry ² , Wanwisa Dejnirattisai ^{1,*} , Jingshan Ren ^{2,*} , David I. Stuart ^{2,3,4,*,^} , Gavin R Screaton ^{1,3,*}
10 17	
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	 Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK Oxford University Hospitals NHS Foundation Trust, Oxford, UK Peter Medawar Building for Pathogen Research, Oxford, UK Translational Gastroenterology Unit, University of Oxford, Oxford, Oxford, UK Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK Nuffield Department of Medicine, University of Oxford, Oxford, UK NiHR Oxford Biomedical Research Centre, Oxford, UK Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, Department of Medicine, University of Oxford, Oxford, UK
38 39 40	15. Department of Paediatrics, University of Oxford, Oxford, UK.
40	# These authors contributed equally to this work.
42 43	 ^{&,\$} See acknowledgements * Corresponding authors: <u>dwanwisa@well.ox.ac.uk</u>, <u>ren@strubi.ox.ac.uk</u>,
44	dave@strubi.ox.ac.uk, gavin.screaton@medsci.ox.ac.uk
45	^ Lead contact
46	

47 Summary

48

49 Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we 50 compare neutralization of Omicron BA.1, BA.1.1 and BA.2. BA.2 RBD has slightly higher 51 ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly 52 associated with its increased transmissibility. Neutralization differences between sub-lineages 53 for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 54 binding site, however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly 55 reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function 56 analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following 57 breakthrough Omicron-BA.1 infection reveals that they are focussed in two main clusters 58 within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection 59 and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic 60 61 strains and many show broad reactivity with variants of concern.

62

63 Introduction

Omicron BA.1 was first reported in late November 2021 in Southern Africa and spread
explosively around the world, becoming the dominant SARS-CoV-2 variant in the UK by 17th
December

(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat
a/file/1042100/20211217_OS_Daily_Omicron_Overview.pdf). Omicron (where not specified
Omicron refers to sub-lineage BA.1) contains an unprecedented number of mutations
concentrated in the Spike (S) gene which carries 30 substitutions plus the deletion of 6 and
insertion of 3 residues.

S is the major surface glycoprotein on the SARS-CoV-2 virion and is involved in viral attachment to target cells via the interaction of cell surface expressed angiotensin converting enzyme 2 (ACE2) with the receptor binding site, at the tip of the receptor binding domain (RBD), in the S1 fragment of S (Lan et al., 2020). Following attachment, cleavage of S releases S1, allowing a major conformational change in S2, exposing a hydrophobic loop which executes fusion of viral and host cell membranes, releasing the viral genome to initiate viral replication (Walls et al., 2017).

80

Since late 2020 a succession of variants of concern (VoC) have emerged. Some have caused 81 large regional outbreaks (Beta (Zhou et al., 2021), Gamma (Dejnirattisai et al., 2021b)) whilst 82 83 others have become dominant globally (Alpha (Supasa et al., 2021) then Delta (Liu et al., 2021a) then Omicron (Dejnirattisai et al., 2022)). All VoC contain mutations in the RBD, 84 which potentially serve two functions. Firstly, to increase affinity to ACE2 and potentially 85 increase transmissibility, this is observed for Alpha, Beta and Gamma (Dejnirattisai et al., 86 87 2021b; Supasa et al., 2021; Zhou et al., 2021). Secondly, mutations have the potential to cause escape from serum induced by vaccines or previous SARS-CoV-2 infection. Escape from 88 neutralization is modest for Alpha, more marked for Beta, Gamma and Delta and more extreme 89 90 for Omicron (Dejnirattisai et al., 2022; Dejnirattisai et al., 2021a; Dejnirattisai et al., 2021b; 91 Liu et al., 2021a; Supasa et al., 2021; Zhou et al., 2021).

92

The extensive mutational burden in Omicron S disrupts the activity of the majority of potent neutralizing mAbs leading to severe knock-down or complete loss of the neutralizing capacity of serum from natural infection or vaccination, contributing to increased transmissibility and explosive spread (Cele et al., 2021; Dejnirattisai et al., 2022). However, it is clear that

97 respectable anti-Omicron titres are achieved following third dose vaccination, providing good 98 protection from hospitalization and severe disease (Dejnirattisai et al., 2022; Mahase, 2021b). 99

100 As of February 2022, two sub-lineages additional to BA.1 have been identified: BA.1.1 and 101 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-**BA.2** 102 19---1-february-2022). Compared to BA.1, BA.1.1 contains an additional R346K mutation (it is thus also known as BA.1+R346K), whilst BA.2 bears 8 unique mutations in S (6 within the 103 RBD, Figure 1A) and lacks 13 mutations found in BA.1. BA.2 is now becoming dominant in 104 several countries (https://www.nature.com/articles/d41586-022-00471-2) and is estimated to 105 106 of account for approximately 93.7% England cases in 107 (https://www.gov.uk/government/news/covid-19-variants-identified-in-the-uk).

108

Here we investigate the Omicron sub-lineages BA.1.1 and BA.2 in addition to BA.1. We report 109 110 slightly increased affinity of BA.2 RBD for ACE2. We show that BA.1.1 and BA.2 are 111 modestly more difficult to neutralize than BA.1 using vaccine serum. Concerningly, a number 112 of mAbs, including those in clinical use (Chen et al., 2021; Mahase, 2021a; Weinreich et al., 2021), show marked differential sensitivity to BA.1 or BA.2 for which we provide structural 113 114 explanations. We describe the generation of a panel of 545 mAbs from volunteers following 115 vaccine break-through Omicron infections and perform detailed analysis of the 28 most potent (IC50 < 100 ng/ml), which all potently neutralized early pandemic SARS-CoV-2 strain 116 117 Victoria and were more heavily mutated than mAbs obtained from primary infections, 118 consistent with them having been recalled and adapted from the response to vaccination. Many 119 are fully cross-reactive amongst early pandemic and all VoC (Victoria, Alpha, Beta, Gamma, 120 Delta and Omicron).

122 **Results**

123 Omicron BA.2 lineage

124 BA.2 shares 21 amino acid substitutions with BA.1, spread throughout S (Figure 1A), however 125 BA.1 has an additional 6 amino acid deletions, 3 insertions and 9 substitutions compared to BA.2, whilst BA.2 has an additional 3 deletions and 7 substitutions compared to BA.1. In the 126 127 RBD, BA.1 contains unique mutations S371L, G446S and G496S and in some isolates R346K (BA.1.1), while BA.2 carries S371F, T376A, D405N and R408S (Figure 1A,B). All of these 128 129 mutations have the potential to differentially affect antibody binding and could modulate 130 neutralization, particularly BA.1 G446S, G496S and BA.2 D405N, R408S which lie at the edge 131 of the ACE2 binding footprint. Residue 371 (which differs between BA.1 (Leu) and BA.2 132 (Phe)) and the BA.1.1 specific R346K change lie close to the N343 glycan and could modulate 133 binding of potent antibodies to this region (Figure 1B). Interestingly, the sub-lineage specific mutations segregate, with BA.1 and BA.1.1 changes lying on one side of the ACE2 footprint 134 and BA.2 changes on the other side (Figure 1B), possibly reflecting different selective pressure 135 136 on the BA.1 and BA.2 sub-lineages.

137

138 Neutralization of BA.1, BA.1.1 and BA.2 by immune sera

To assess differential sensitivity to neutralization of the Omicron sub-lineages, we performed neutralization assays on Victoria (an early pandemic isolate containing an S247R substitution in the S NTD compared to the Wuhan vaccine strain), together with BA.1, BA.1.1 and BA.2 viruses using sera collected from vaccinees 28 days following third doses of the Oxford/AstraZeneca AZD1222 (n=41) or Pfizer/BioNtech BNT162b2 (n=20) vaccines (**Figure 1C,D**).

There was a major reduction in neutralization titre for all Omicron viruses for both vaccines. For AZD1222 vaccinees, BA.1.1 and BA.2 showed small but significant reductions in titres relative to BA.1; BA.1 *vs.* BA.1.1, 1.5-fold reduction (p=0.0005) and BA.1 *vs.* BA.2 1.4-fold reduction (p=0.02). BNT162b2, following the third vaccine dose, showed the same trend; BA.1 *vs.* BA.1.1, 1.5-fold reduction (p=0.0049) and BA.1 *vs.* BA.2, 1.2-fold reduction (p=0.0637) (**Figure 1C,D**).

152

Next, we looked at the neutralization profile across all VoC for serum collected from cases 153 154 infected with BA.1. Early samples (n=12) were taken ≤ 14 days from symptom onset (median 155 13 days), later samples (n=16) were taken ≥ 21 days following symptom onset (median 38) days). All cases had received at least 2 doses of vaccine (4 AZD1222, 16 BNT162b2 and 1 156 157 Johnson & Johnson JNJ-78436735) and 3 of the late convalescent cases received a third dose of vaccine following Omicron infection. Neutralization was tested using live virus assays 158 159 (Figure 1E). At early time points, as expected, all vaccinated cases had high titres to Victoria 160 with geometric mean FRNT50 close to 1/3000 and exhibited broad neutralization of VoC with 161 FRNT50 > 1/1000 for all viruses except Omicron (FRNT50 = 558). At the later time point, titres were increased against all variants including BA.1 (3.1-fold p=0.0097), although titres to 162 163 Victoria were only modestly increased. Comparison of early and late samples taken from the same individuals confirmed the broad boosting of the response following Omicron infection 164 165 (Figure S1A).

166

167 Potently neutralizing antibodies isolated following Omicron infection

We generated a panel of human monoclonal antibodies from volunteers who had recovered from sequence confirmed BA.1 infection having previously received 2 doses of the Pfizer-BioNtech vaccine. First, we performed neutralization assays against BA.1 and Victoria. In all cases the BA.1 neutralization titre, measured by the serum dilution required to reduce virus
foci by 50% (FRNT50) was above 100 (Figure S1B).

173

B cells from 5 donors were stained with full length BA.1 trimer and single cells sorted by FACS (**Figure S1C**). Following a degenerate RT-PCR reaction, heavy and light chain sequences were assembled into expression vectors using the Gibson reaction and transfected into 293T cells. Culture supernatants were screened for reactivity to full length BA.1 or WT S (wild type Wuhan) together with BA.1 RBD and NTD. In total 1,122 single cells were sorted and 545 mAbs recovered.

180

Almost all mAbs cross-reacted between WT and BA.1 S by ELISA (**Figure 2A**). Compared with a previous panel of monoclonal antibodies we produced from naïve cases infected early during the pandemic we found a higher proportion of RBD-reactive mAbs: 56% compared to 21% (binomial two-population proportion test, p<0.0001, Z~10) (**Figure 2B**). Underscoring this, in a similar study on early pandemic samples (Zost et al., 2020a), raw data on unsorted Bcells showed a similar proportion (23%) of RBD-reactive mAbs. Some 50% of the remaining antibodies (129/545) bound the NTD.

188

189 Characterization of the most potent Omicron monoclonal antibodies

Neutralization assays were used to select the 28 most potent antibodies, with BA.1 FRNT50
titres < 100 ng/ml. All but one of these bound the RBD (Omi-41 bound the NTD), but none
cross-reacted with SARS-CoV-1 S protein by ELISA. With the exception of Omi-30 and Omi41 they reduce the interaction of RBD with ACE2, Figure 2C. However, several IGHV1-69
antibodies were less effective blockers (Figure 2C).

196 Examination of the heavy chain gene family usage (Figure 2D, Table S1) revealed Omi-32 and Omi-33, which differed by 5 amino acids, were clonally related (VH3-33). 30% (9/28) of 197 the monoclonals belong to the IGHV3-53 and related IGHV3-66 gene families. These 198 199 antibodies generally bind a site at the back of the neck of the RBD and block ACE2 binding 200 (Dejnirattisai et al., 2021a). They form the best-known public antibody response to SARS-201 CoV-2 infection (Yuan et al., 2020; Dejnirattisai et al., 2021a, Liu et al., 2021b) with a similar incidence (7/20) seen in potent early pandemic antibodies (Dejnirattisai et al., 2021a). 202 However, those raised against early pandemic virus have little activity on VoC containing the 203 N501Y mutation (Alpha, Beta, Gamma, (Supasa et al., 2021)). We previously described 204 205 IGHV3-53 antibodies (mAb 222 and Beta-27) resistant to the N501Y change (Dejnirattisai et 206 al., 2021b, Liu et., 2021b), but even these show little activity to BA.1 or BA.2 (Figure S1D,E) 207 (Dejnirattisai et al., 2022; Dejnirattisai et al., 2021b).

208

Roughly one half of the gene families we observed in the potent early pandemic antibodies are also represented in the Omicron set (**Figure 2D**). Although IGHV1-69 did not feature in our potent early antibodies it has been seen by others in a number of potent mAbs isolated following natural infection or vaccination (Wang et al., 2021; Andreano et al., 2021; Cho et al., 2021). We found 6 IGHV1-69 antibodies (2, 24, 30, 31, 34 and 38) out of 27 potent RBD binders.

215

We found higher levels of somatic mutation in both heavy and light chains of Omicron mAbs than in the early pandemic set of antibodies; mean number of amino acid substitutions 9.00/6.00 for Omicron and 4.55/4.25 for early pandemic (p<0.0001 and p=0.0026) for heavy and light chains respectively (**Figure 2E**).

220

221	The potency of these antibodies is underscored by SPR measurements of the binding of 6
222	selected mAbs to BA.1 RBD. The antibodies bind very tightly with affinities between 5 nM to
223	120 pM (Figure S2A-F, for clarity SPR results are grouped in Figure S2A-O).
224	
225	Broad neutralization of VoC by potent Omicron antibodies
226	Live virus neutralization assays show that FRNT50 titres to Victoria are < 100 ng/ml for all 28
227	potent mAbs (Figure 3A, Table S2A), perhaps because the antibodies have been derived from

vaccine induced memory B cells. 5/28 antibodies (Omi-3, 8, 12, 18, and 24) neutralize BA.1

229 with FRNT50 titres < 10 ng/ml (9, 8, 4, 6, and 7 ng/ml respectively) with FRNT90 titres of

230 189, 101, 44, 33, and 83 ng/ml respectively.

231

228

232 Live virus neutralization assays against Alpha, Beta, Gamma and Delta VoC show 17/28 antibodies are cross-reactive against all VoC with <10-fold difference in FRNT50 titres 233 234 between all viruses (Figure 3A, Table S2A). Omi-6, 24, 30, 31, 34 and 41 show reduced or 235 absent activity against Delta, and 4 of these belong to the IGHV1-69 family, whose epitope may impinge on the L452R Delta mutation (Delta only has 2 RBD mutations and shares 236 237 T478K, with BA.1). Antibodies Omi-9 and 32 perform poorly on Beta and Gamma and may 238 be sensitive to E484K found in these VoC, but tolerate the E484A change in Omicron (Omicron 239 shares N501Y and K417N mutations with Beta whilst Gamma has N501Y, K417T). 240 Interestingly, one IGHV1-69 antibody, Omi-38, showed some enhancement of BA.1 infection 241 at lower concentrations, up to 63% higher infection than the control without antibody. This was 242 not seen for other SARS-CoV-2 variants against Omi-38.

243

Finally, of 129 anti-NTD mAbs isolated, only one, Omi-41, showed FRNT50 titres < 100 ng/ml. Omi-41 showed neutralizing activity against Victoria, Alpha and Gamma but no activity

- against Beta and Delta, presumably reflecting the unique spectrum of NTD changes found inthese viruses.
- 248
- 249 Neutralization of Omicron sub-lineages by potent antibodies
- For all 28 potent Omicron antibodies, neutralization assays of BA.1, BA.1.1 and BA.2 were performed using live virus (**Figure 3B Table S2A**). Most showed little difference between BA.1, BA.1.1 and BA.2. However, there were notable exceptions; BA.2 neutralization was reduced 189, 79 and 26-fold compared to BA.1 for Omi-8, 32 and 33 respectively, while BA.1.1 neutralization was reduced 28 and 193-fold compared to BA.1 for Omi-6 and 32 respectively and knocked out for Omi-38 and 39. In line with this, SPR analysis showed that binding of Omi-8 to BA.2 is 5-fold weaker than to BA.1 (**Figure S2F,G**).
- 257

Pseudoviral neutralization curves for panels of antibodies isolated from early pandemic and Beta cases against BA.1, BA.1.1 and BA.2 are shown in **Figures S1D,E** and **Table S2B**; in most cases titres are similar, but mAbs 40, 278 and 318 neutralize BA.2 > BA.1, whereas early pandemic mAb 222, Beta-22, 29, 54, 55 and 56 neutralize BA.1 > BA.2, whilst Beta-53, which binds close to the N343 glycan shows reduced neutralization of BA.1.1.

- 264 *Neutralization of Omicron sub-lineages by antibodies developed for clinical use*
- Neutralization assays against Victoria, BA.1, BA.1.1 and BA.2 for clinical mAbs revealed a
 number of differences (Figure 3C, Table S2A).

267

REGN 10987 and 10933: REGN 10933 (Weinreich et al., 2021) binds the back of the left shoulder and 10987 binds the right shoulder. REGN10933 H2 contacts residues 484 and 493 and is sensitive to the E484K mutation. Since E484A and Q493R are present in all Omicron

strains, neutralizing activity to Omicron is universally lost. REGN10987 H2 contacts residue
446 and has no activity against Omicron variants containing G446S, but retains some
neutralization capability against BA.2 which lacks the G446S mutation.

274

AZD8895 & AZD1061: AZD8895 and AZD1061 bind the back of the left shoulder and the front of the right shoulder respectively. AZD1061 can neutralize BA.2 (<10-fold reduction compared to Victoria), but activity against BA.1 is markedly reduced and neutralization of BA.1.1 is knocked out. This is due to the LC CDR2 contacting G446S in BA.1 and the R346K (BA.1.1) mutation making strong interactions with the HC CDR3. AZD8895 shows reduced neutralization due to the H2 contacts with the Q493R mutation universally present in the Omicron lineage (**Figure 3C**).

282

LY-CoV016 and 555: Activity of both antibodies on the entire Omicron lineage is knocked out.
LY-CoV016 (IGHV3-53) makes extensive interactions with N501 and Y505 via L1 and L3
making it sensitive to mutations at these residues. LY-CoV555 (Sun and Ho, 2020) is
vulnerable to the E484K mutation in Beta (Liu et al., 2021a) but likely tolerates E484A
however, contacts with the universal Omicron Q493R mutation will abrogate binding across
the board.

289

Vir-S309: S309 (Dejnirattisai et al., 2021a; Pinto et al., 2020; Sun and Ho, 2020) retains some
activity across the Omicron lineage, but notably less against BA.2. S309 binds the right flank
with H3 contacting G339 and the N343 glycan which is close to the serine 371, 373 and 375
mutations. 371 is a Phe in BA.2 compared to a Leu in BA.1 and superposition of the structure
of BA.1 in complex with S309 (McCallum et al., 2022) on our BA.2 structure (see below)
shows that the bulky Phe protrudes outwards disturbing the glycan attached to residue 343 of

the RBD (**Figure 4A**). This sugar is critical for S309 binding, explaining the 126-fold reduction of neutralization titre to BA.2 compared to Victoria. Furthermore, neutralization of BA.1.1 is 4-fold worse than BA.1, due to the R346K mutation, since the shortened side chain cannot

300 BA.2 is approximately 20-fold worse than BA.1, consistent with SPR analysis which showed

interact as effectively with Asp 93 of the S309 heavy chain (Figure 4B). Neutralization of

301 that binding to BA.2 ~15-fold weaker than to BA.1 (Figure S2H,I).

302

296

297

298

299

303 *Quantitative dissection of the nature of the Omicron mAb responses*

We applied a neutralization-correlation method, which takes neutralization results for mAbs 304 305 against various virus strains, calculates correlation coefficients for all possible pairs of mAbs 306 and then clusters the mAbs (Dejnirattisai et al., 2021a). Pseudovirus neutralization data (Figure 307 4C) for early pandemic (Dejnirattisai et al., 2021a), Beta (Liu et al., 2021b) and BA.1 antibodies revealed (Figure 4D, Video S1) clear differences between the three sets. The BA.1 308 antibodies are almost entirely separated from early pandemic mAbs, presumably by 309 310 selection/somatic mutations. BA.1 antibodies are also largely distinguishable from Beta 311 antibodies after clustering, but a subset of Beta antibodies (Beta-27, Beta-40, Betas-47-50, Betas-53-56, two of which belong to gene family IGHV1-69), share greater similarity with 312 313 Omicron antibodies. Further cluster dissection of the Omicron antibodies (Figure 4E) segregates five which have a different neutralization profile due to drop-out against Delta 314 315 (Omi-6, -24, -30, -31, -34), four of these are IGHV1-69.

316

317 Fine mapping of RBD binding Omicron antibodies using competition measurements

318 Detailed 3D maps of the binding positions of antibodies can be obtained by combining 319 competition data and some known antibody positions (Dejnirattisai et al., 2021a). We therefore 320 performed pairwise biolayer interferometry (BLI) competition measurements on the 27 potent

RBD binding Omicron mAbs and several pre-pandemic mAbs of known binding position and obtained a map with average positional error of 9 Å. The mAbs segregate into two principal clusters, which are a subset of the epitopes observed for the early pandemic virus and distinct from the focus seen for Beta (**Figure 5A-D**) (Dejnirattisai et al., 2021a; Liu et al., 2021b).

325

326 The first antibody cluster includes the IGHV3-53 and IGHV3-66 type antibodies and is towards the back of the neck/left shoulder, extending up to the top of the left shoulder. This region 327 328 corresponds to the major epitope for potent neutralizers in our early pandemic antibody panel 329 (Figure 5B,D). Omi-9, which shows reduced neutralization of Beta and Gamma, positions 330 close to residue 484 which is mutated from Glu to Lys in Beta/Gamma and to Ala in Omicron. 331 The second, right shoulder, cluster was seen in the full set of early pandemic antibodies, above the S309 site (Figure 5A). This region is occupied by 5 of the 6 IGHV1-69 mAbs, the other, 332 Omi-2. lies within the neck/left-shoulder cluster. IGHV1-69 mAbs Omi-24, 30, 31 and 34, 333 334 which show reduced neutralization of Delta are placed close to residue 452 which is mutated 335 from Leu to Arg in Delta. Omi-6, an IGHV4-4 antibody with reduced Delta neutralization (Figure 3A) occupies a similar position to the major cluster of IGHV1-69 antibodies. 336

337

338 Structures of anti-Omicron Fab/RBD and Fab/spike complexes

To further understand the basis of cross-reactivity and potency we determined a number of structures by crystallography and cryo-EM (**Tables S3, 4, Figures S3, S4A-E, G-I,5E,6**), to give structural information on the binding of 11 of the 28 most potent antibodies, although for several the resolution was limited, and for some a structurally characterised nanobody (Huo et al., 2021) or Fab, or both (Zhou et al. 2020; Dejnirattisai *et al.* 2021a; Liu et al. 2021b) were required as crystallization chaperones. The binding sites show excellent agreement with those 345 determined from the competition measurements, falling into two broad binding areas (Figures
346 5E,6A).

347

348 Back of the neck/left shoulder epitope binders

Omi-3 and -18 are representative of IGHV3-53 and IGHV3-66 antibodies that bind at the back 349 350 of the neck and account for 9/28 of the most potent antibodies. They show how these antibodies can be adapted to broadly neutralize all major SARS-CoV-2 variants (Figure 6B). A problem 351 for many IGHV3-53/66 antibodies is that most VoC harbour mutation N501Y, which 352 introduces a steric clash with the LC CDR1 (L1) abrogating binding. However, we have 353 354 previously reported two mechanisms for avoiding this clash (Dejnirattisai et al., 2021b; Liu et 355 al., 2021b), by (i) mitigating the contact by inserting a Pro into the L1 loop or (ii) shifting the L1 loop away from N501Y (Dejnirattisai et al., 2021b; Liu et al., 2021b). Omi-3 achieves 356 resilience by repositioning the L1 loop in a mechanism similar to (ii), whilst Omi-18 shortened 357 the L1 loop, which becomes flexible enough to accommodate mutations at residues 501 and 358 505 (Figure S3, Figure 6B). 359

360

We have determined structures for five mAbs within the neck/left shoulder cluster, Omi-2, -9, 361 -12, -25 and -42. Some broadly neutralize all VoC while others are sensitive to the mutations 362 at residue 417 and 484 found in Beta and Gamma (explained for Omi-25 in Figure S4A). In 363 364 terms of overall pose Omi-9 is an outlier, being perched upright on the RBD, whilst the others approach from the back (Figure 5E). Omi-2 belongs to the IGHV1-69 gene family but has 365 features in common with Omi-12, the only member of the IGHV1-58 gene family found in the 366 367 set of 28 potent antibodies. In particular, Omi-2 and Omi-12 have a disulphide bond and Pro and Phe residues at the same positions in the H3 loop which mediate interactions with F486 of 368 the RBD, these commonalities appear to drive Omi-2 to adopt almost exactly the same pose as 369

- 370 Omi-12, which differs from the other potent antibodies that bind in this region (Figure 6A).
- 371 Note that while Omi-12, like many other IGHV1-58 antibodies, is glycosylated in the H3 loop,
- 372 Omi-2 is non-glycosylated (Dejnirattisai et al., 2021a; Liu et al. 2021b).
- 373
- 374 Front of right shoulder epitope binders

375 This cluster harbors all IGHV1-69 mAbs except Omi-2. As expected, these antibodies (structures obtained for Omi-31 and -38) attack the RBD from the front and sit above the 376 binding site of Vir-S309. Changes, especially in the H3 loops, explain their differing 377 378 specificities (Figure S3). Omi-6 and -32 bind at the same site, although Omi-6 binds a little 379 lower and Omi-32 is rotated clockwise by $\sim 90^{\circ}$ (Figure 6). The specific sensitivities of these antibodies to Delta and BA.1.1 is explained in Figures S3. S4B-D. Omi-32 induces a large 380 rearrangement in the 446 loop of the BA.1 RBD (Figure 4E). Omi-32 and -33 are clonally 381 related and bind in the same way. Omi-33 showed 41-fold greater activity against BA.1.1 than 382 383 Omi-32 (Figure 3B), this is because mutations in contact residues in L1 and H1 allow Omi-33 to better tolerate the change at 346 in BA.1.1. Antibodies binding at this epitope tend to be less 384 385 broadly cross-reactive than those binding to the neck/left shoulder, due to a high concentration of mutations in the VoC, notably residues 346, 446, 452, 496 and 498. 386

387

388 Example of RBD mutations repositioning an early pandemic mAb

389 Detectable residual activity for mAb 150 (IGHV3-53) was observed with BA.1, BA.1.1 and 390 BA.2 (**Table S2B**). Structural analysis (**Table S3**) revealed binding to be broadly similar to 391 that observed previously for early pandemic virus (Dejnirattisai et al., 2021a), although the Fab 392 was translated by several Å and formed looser interactions, consistent with almost complete 393 loss of neutralization activity.

395 Effects of somatic mutation

396 In a set of potent early pandemic antibodies the IGHV1-58 gene family was the second most 397 highly represented (4/20) (Dejnirattisai et al., 2021a), however, they constitute only 1/28 in the 398 Omicron set, and it is notable that other IGHV1-58 antibodies such as AZD8895 and 399 representatives from our previous studies such as mAbs 55, 165, 253 and Beta-47 show large 400 or complete loss of neutralization activity against Omicron BA.1 (Figure 3C, S4F) (Dejnirattisai et al., 2021a). The structural basis for the retention of activity of Omi-12 on BA.1 401 402 appears to be a somatic mutation in the HC CDR2 loop (V53P) which allows the RBD mutation 403 Q493R to be accommodated (Figure S4G). Overall, we found higher levels of somatic 404 mutation in both heavy and light chains of Omicron mAbs than in the early pandemic set of 405 antibodies. Taking the IGHV1-69 gene family as an exemplar (Figure S4H), the changes are 406 largely focused on the H2 and H1 loops, and residues adjacent to them in the sequence and in the 3D structure (notably the DE loop), with almost none at the interface with the LC. 407

408

409 Structure of BA.2 RBD and ACE2 affinity

410 We determined the structure of BA.2 RBD in complex with ACE2 (Table S3). As expected 411 the BA.2 RBD structure is very similar to that of BA.1 (Dejnirattisai et al., 2022, Han et al., 412 2022, McCallum et al., 2022). Although the three serine residues mutated in BA.1 RBD: 413 S371L, S373P and S375F are also mutated in BA.2, the mutation at 371 is to a Phe, representing 414 a single codon mutation from early pandemic viruses, whereas the S317L mutation in BA.1 415 requires two mutations in the codon. BA.2 may therefore have features common to earlier 416 versions of the Omicron lineage. The bulkier Phe protrudes from the structure in BA.2. In 417 addition, the independent views provided by different crystal forms show that it adopts a range of conformations (Figure 7A), likely due to differing crystal contacts, reflecting flexibility in 418

this loop region (also flexible in other variants). These changes may affect the presentation of
the RBDs (Dejnirattisai et al., 2022).

421

422 We measured the affinity of BA.1 and BA.2 Spike and RBD for ACE2 by SPR (Figure S2J-O). The affinity of BA.2 RBD was slightly increased compared to early virus and BA.1 (~2-423 424 fold, $K_D = 4.0$ nM), although affinities are similar among the three Spikes. The RBD binding probably gives the best indication of the intrinsic ACE2 affinity and as reported earlier 425 (Dejnirattisai et al., 2022), the affinity of RBD for BA.1 was on a par with that of the early 426 427 virus, 7.8 nM and 7.3 nM respectively (binding data for Omicron RBDs are shown in Figure 428 S2A-L together with the binding of selected mAbs), implying that the increased affinity 429 imparted by S477N, Q498R and N501Y is counter balanced by other mutations in the ACE2 430 footprint. Earlier measurements of the contributions of individual mutations to binding affinity (Dejnirattisai et al., 2022) show that G496S and the triple-mutation S371L, S373P and S375F 431 reduce binding by 2-fold and 2.2-fold respectively, whereas BA.2 lacks G496S and has S371F. 432 433 This may account for some of the difference, but more likely mutations on the edge of the 434 ACE2 footprint (R408S & D405N only present in BA.2, G446S & G496S only present in BA.1) enhance binding of BA.2 to ACE2. This is confirmed by the structure of the BA.2/ACE2 435 436 complex (Table S3, Figure 7B-D), which shows the same mode of engagement, with marginal 437 additional binding conferred by improved charge complementarity with ACE2. Structural 438 differences are observed at RBD residue G446 and at ACE2 H34 whose side chain has rotated 439 ~120° relative to the BA.1 RBD/ACE2 complex (Han et al., 2022; McCallum et al., 2022).

440

441 The Antigenic Cartography of the Omicron sub-lineages

442 Using early pandemic, Alpha, Beta, Gamma, Delta, BA.1 sera together with vaccine sera in

443 pseudoviral neutralization assays against Victoria, Alpha, Beta, Gamma, Delta, BA.1, BA.1.1

and BA.2, including some published data (Dejnirattisai et al., 2022; Dejnirattisai et al., 2021a; 444 Dejnirattisai et al., 2021b; Liu et al., 2021a; Supasa et al., 2021; Zhou et al., 2021) we have 445 extended the analysis recently reported for BA.1, modelling individual viruses independently 446 447 and allowing for serum-specific scaling of the responses (Dejnirattisai et al., 2022). The measured and modelled responses are shown in Figure S2P (with 1238 observations and 332 448 449 parameters the residual error is 20.8%). The variant map is well described in three dimensions and presented in Video S2, with orthogonal projections shown in Figure 7E. Early pandemic, 450 451 Alpha, Beta, Gamma and Delta are roughly in a plane centred on the early pandemic virus. The 452 Omicron sub-lineages are grouped together at a considerable distance from the earlier viral variants. BA.1 and BA.1.1 clustered very closely together and BA.2 more distant. 453

454

455 Discussion

The emergence of the highly transmissible Omicron variant and its extremely rapid global spread led to considerable concern, however early data from South Africa that Omicron led to less severe disease has been borne out in waves of infection in other countries (Nealon and Cowling, 2022). Nevertheless, because of the very large number of infections there remains considerable pressure on healthcare systems and significant numbers of deaths.

461

BA.1 and BA.2 were first reported at nearly the same time in November 2021. The BA.1 sublineage dominated the wave of Omicron infection in South Africa, but the proportion of Omicron infections caused by BA.2 has been increasing in several countries and it is now dominant in Denmark, India and the UK. It seems that BA.2 has a small transmission advantage over BA.1 and although there is no clinical evidence of increased disease severity, there is a suggestion from animal studies that this may be the case (Yamasoba et al., 2022). The sequence differences between these sub-lineages are likely to alter the antigenicity of S such that reduced

469 vaccine efficacy against BA.2 *vs* BA.1 may be driving the transmission advantage or 470 alternatively may be increasing BA.2 receptor affinity. In line with this, we show a slight 471 increase in the affinity of BA.2 RBD for ACE2 compared with BA.1 and a modest reduction 472 in neutralization titres of BA.2 *vs*. BA.1 in vaccine serum, which is borne out in the antigenic 473 cartography (**Figure 7E, Video S2**).

474

Following three doses of vaccine, particularly BNT162b2, good neutralizing titres of antibody 475 476 against BA.1, BA.1.1 and BA.2 are induced, with only minor differences between them. 477 Breakthrough Omicron infection in previously vaccinated individuals leads to an antibody 478 response broadly effective against all VoC including Omicron lineages. The similarity in 479 neutralization titres suggests that reinfection of BA.1 exposed and vaccinated cases with BA.2 would be unlikely, at least in the short term, however, the concurrent high levels of infection 480 by BA.1 and BA.2 have led to the identification of a BA.1/BA.2 recombinant virus XE 481 (https://www.gov.uk/government/news/covid-19-variants-identified-in-the-uk). All the potent 482 483 mAbs generated cross-neutralize Victoria and many are broadly reactive against VoC. These 484 responses may be recalled from memory B cells generated following vaccination but since we do not have paired samples to analyze repertoire following vaccination before Omicron 485 486 infection this remains conjecture. It is noteworthy that vaccination and in particular third dose vaccination, has been shown to induce a broader antibody response to VoC (Röltgen et al., 487 488 2022; Muecksch et al., 2022), targeting more conserved regions, than occurs following natural 489 infection (https://doi.org/10.1016/j.cell.2022.01.018, PMID: 35194607).

490

491 Overall, the potent antibodies form two clusters (Figure 5B); the first, at the neck/left shoulder,
492 includes antibodies that bind the back of the neck (*e.g.* IGHV3-53 antibodies) and those that
493 bind more upright on the left shoulder (Omi-9); the second, on the front of the right shoulder

494 is seen in the full set of our early pandemic antibodies, but does not include any of the highly 495 potent antibodies in that set. Although most of the potent Omicron antibodies cross-neutralize 496 all VoC, a subset shows poor or absent neutralization of Delta or Beta/Gamma. Omi-12, the 497 most potent of the set of 28, belongs to the IGHV1-58 gene family which has been isolated on 498 several occasions following SARS-COV-2 infection. It is anomalous in that it cross-neutralizes 499 all VoC whilst other IGHV1-58 antibodies lose activity against BA.1 and this potency is 500 recovered by somatic mutation.

501

The IGHV3-53 and IGHV3-66 families (9/27), form the most frequent public antibody response in the Omicron set and in the response to early pandemic virus (Dejnirattisai et al., 2021a; Yuan et al., 2020). Most early pandemic examples show reductions or loss of activity on 501Y containing VoCs and we find that the appropriate length of H3 and L3 together with other changes in H3 can place L1 to accommodate 501Y and other mutations present in the Omicron lineage (**Figure 6B**).

508

The second most abundant IGHV family amongst the Omicron antibodies (6/27) was IGHV1-69, which also featured in a panel of potent mAbs isolated from Beta infected cases (Liu et al., 2021b). We find that most of these bind in a similar way to the right shoulder, with several affected by the R346K mutation on BA.1.1, presumably due to stabilizing contacts analogous to that seen for S309 (**Figure 7F**). Interestingly the exception to this binding pattern is Omi-2 which binds in the other major cluster (**Figure 6A**).

515

516 Whilst the neutralization properties of most Omicron monoclonal antibodies isolated in this 517 study did not show differences against BA.1, BA.1.1 and BA.2, some clinical mAbs showed 518 differences, in particular REGN10987 regained some activity against BA.2 and AZD1061

519 regained most activity against BA.2 but lost activity against BA.1.1 compared to BA.1. Of 520 particular concern S309, the activity of which is already reduced 6-fold against BA.1 521 (Dejnirattisai et al., 2022), was reduced a further 4-fold against BA.1.1 and a further 20-fold 522 against BA.2. Although in the short term, genotyping may allow more efficient targeting of mAb therapy, there is a need to develop new Omicron specific antibodies to add to existing 523 524 SARS-CoV-2 monoclonal antibody cocktails, or to develop broadly cross-reactive antibodies, to provide pre-exposure prophylaxis or post exposure treatment to the many 525 526 immunosuppressed patients unable to mount protective responses following vaccination.

527

528 In summary, we have presented a structure-function analysis of potent human antibodies 529 induced by Omicron BA.1 breakthrough infection in SARS-CoV-2 vaccinated individuals. 530 Many show broad activity against all VoC and may have been generated from vaccine memory responses. Overall, the structural studies demonstrate there is still space available on the RBD 531 532 for the binding of potent mAbs able to broadly neutralize variants of concern. It also illustrates 533 the extraordinary plasticity of the public antibody responses through IGHV3-53/66 and IGHV1-58 where neutralizing activity against BA.1 and other VoC can be restored by variation 534 in CDR length and somatic mutation. 535

536

537 *Limitations of the Study*

Some limitations of this study are that as the neutralization assays are performed *in vitro* they are not affected by antibody dependent cellular cytotoxicity or complement-dependent cytotoxicity which may augment the function of poorly neutralizing antibody *in vivo*. Furthermore, we have not studied the effects of the T cell response, which is known to withstand changes in the VoC more robustly than the antibody response and to persist, which

may contribute to the protection from severe disease if the antibody response fails to blockinfection.

545

546 Acknowledgements

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation 547 548 Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002) to D.I.S. and G.R.S. We are also grateful for support from Schmidt Futures, the Red Avenue Foundation and 549 550 the Oak Foundation. G.R.S. was supported by Wellcome, H.M.E.D., and J.Ren by Wellcome (101122/Z/13/Z), D.I.S. and E.E.F. by UKRI MRC (MR/N00065X/1). D.I.S. and G.R.S. are 551 552 Jenner Investigators. This is a contribution from the UK Instruct-ERIC Centre. AJM is an 553 NIHR-supported Academic Clinical Lecturer. Convalescent sampling was supported by the 554 UKRI MRC (MC_PC_19059 awarded to the ISARIC-4C consortium, full contributor list available at https://isaric4c.net/about/authors/) and the National Institutes for Health and 555 556 Oxford Biomedical Research Centre and an Oxfordshire Health Services Research Committee 557 grant to AJM. The Wellcome Centre for Human Genetics is supported by Wellcome (grant 090532/Z/09/Z). Computational aspects were supported by the Wellcome (203141/Z/16/Z) and 558 559 the NIHR Oxford BRC. SPR measurements were carried out ant the Molecular Biophysics 560 facility, University of Oxford.

561

562 Oxford Vaccine work was supported by UKRI, Coalition for Epidemic Preparedness 563 Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical 564 Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network. We 565 thank the Oxford Protective T-cell Immunology for COVID-19 (OPTIC) Clinical team 566 (Christopher Conlon, Alexandra Deeks, John Frater, Lisa Frending, Siobhan Gardiner, Anni 567 Jämsén, Katie Jeffery, Tom Malone, Eloise Phillips, Lucy Rothwell, Lizzie Stafford) for

568 participant sample collection and the Oxford Immunology Network Covid-19 Response T cell Consortium for laboratory support. We acknowledge rapid sharing of Victoria, B.1.1.7 and 569 570 B.1.351 isolated by scientists in the National Infection Service at PHE Porton Down, and 571 B.1.617.2 virus was kindly provided Wendy Barclay and Thushan De Silva. We thank The Secretariat of National Surveillance, Ministry of Health Brazil for assistance in obtaining P.1 572 573 samples. This work was supported by the UK Department of Health and Social Care (DHSC) as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) 574 Consortium, the UK Coronavirus Immunology Consortium (UK-CIC) and the Huo Family 575 Foundation. EB and PK are NIHR Senior Investigators and PK is funded by WT109965MA 576 577 and NIH (U19 I082360). SJD is funded by an NIHR Global Research Professorship 578 (NIHR300791). DS is an NIHR Academic Clinical Fellow. The views expressed in this article 579 are those of the authors and not necessarily those of the National Health Service (NHS), the DHSC, the National NIHR, the MRC or Public Health, England. 580

581

582 Author Information

583 These authors contributed equally: R.N., D.Z., A.T., H.M.G., P.S., C.L., J.H., A.J.M.

584

585 **Contributions**

586 J.H. performed interaction affinity analyses. D.Z. performed antibody competition analyses.

587 D.Z., J.H., J.R., N.G.P., M.A.W., and D.R.H. prepared the crystals and enabled and performed

588 X-ray data collection. J.R., E.E.F., H.M.E.D. and D.I.S. analyzed the structural results. G.R.S.,

- 589 J.H., J.M., P.S., D.Z., R.N., A.T., A.D-G., W.D. and C.L. prepared the RBDs, ACE2, and
- 590 antibodies, and W.D., C.L., and P.S. performed neutralization assays. P.S. and W.D. isolated
- all Omicron variants. D.C., H.W., B.C., and N.T. provided materials. H.M.G. wrote mabscape
- and performed mapping and cluster analysis, including sequence and antigenic space analyses.

A.J.M., D.S., T.G.R., A.A., S.B., S.A., S.A.J., P.K., E.B. S.J.D., A.J.P., T.L., and P.G. assisted
with patient samples and vaccine trials. E.B., S.J.D., and P.K. conceived the study of vaccinated
healthcare workers and oversaw the OPTIC Healthcare Worker study and sample
collection/processing, G.R.S., and D.I.S. conceived the study and wrote the initial manuscript
draft with other authors providing editorial comments. All authors read and approved the
manuscript.

599

600 **Declaration of Interests**

G.R.S. sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ 601 602 Biotechnology. Oxford University holds intellectual property related to the Oxford-Astra Zeneca vaccine. A.J.P. is Chair of UK DHSC Joint Committee on Vaccination & Immunisation 603 604 (JCVI) but does not participate in the JCVI COVID-19 committee, and is a member of the WHO's SAGE. The views expressed in this article do not necessarily represent the views of 605 606 DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with 607 AstraZeneca on coronavirus vaccine development. T.L. is named as an inventor on a patent 608 application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an 609 unrelated project whilst the study was conducted. The University of Oxford has protected 610 intellectual property disclosed in this publication. S.J.D. is a Scientific Advisor to the Scottish 611 Parliament on COVID-19.

612

613

614 **Figure legends**

615

Figure 1 The sub-lineages of Omicron and neutralization of BA.1 and BA.2 by vaccine
and Omicron serum. (A) Comparison of the mutations of Omicron BA.1, BA.1.1 and BA.2

618 RBDs. (B) Position of these on the RBD (grey surface with the ACE2 footprint in dark green). 619 Mutations common to all three are shown in white, those common to BA.1 and BA.1.1 in cyan, 620 those unique to BA.1.1 in blue and those unique to BA.2 in magenta. Residue 371 (yellow) is 621 mutated in all Omicron viruses but differs between BA.1 and BA.2. The N343 glycan is shown 622 in a transparent surface. (C)-(D) Live virus neutralization. of Victoria, BA.1, BA.1.1 and BA.2 623 28 days following the third doses of AZD1222 (n=41) (C), BNT162b2 (n=20) (D). (E) Live virus neutralization assays with VoC using sera obtained < 14 days (median 13 days) and >21 624 625 (median 38 days) following symptom onset. Geometric mean titres are shown above each 626 column. The Wilcoxon matched-pairs signed rank test (C and D) and Mann-Whitney test (E) 627 were used and two-tailed P values calculated.

628

Figure 2 Generation of a panel of Omicron mAbs. (A) ELISA of 525 mAb comparing OD against Wuhan and BA.1 S trimer, further mapping to RBD (Red), NTD (Blue) and non-RBD/NTD (Orange) is indicated (B) Proportion of RBD and NTD binding antibodies found in the Omicron mAb compared to early pandemic mAb. (C) Effect of mAb on binding of ACE2 to BA.1 S trimer. (D) Heavy and Light chain variable gene usage. (E) Somatic mutations found in the potent Omicron mAb (FRNT50 < 100 ng/ml) compared to the early pandemic set. See also Table S1.</p>

636

Figure 3. Neutralization assays against Omicron and VoC. Live virus neutralization curves
using Omicron mAb (A) Victoria, Alpha, Beta, Gamma, Delta and Omicron BA.1 viruses, (B)
neutralization of Victoria, BA.1, BA.1.1, BA.2 viruses. (C) neutralization of Victoria, BA.1,
BA.1.1, BA.2 by antibodies being developed for commercial use. See also Figure S1 and
Table S2A,B.

643 Figure 4 Reasons for attenuation of S309 in different Omicron sub-lineages and correlation of neutralisation between antibodies from different responses. (A) S309 is 644 shown as a semi-transparent surface (heavy chain red, light chain blue) with the glycan attached 645 646 to residue 343 of the RBD drawn as sticks. BA.2 RBD is shown in dark pink (Table S3A) and BA.1 RBD (PDB:7TLY) in grey. The RBD's have been superimposed. Contacts < 2.0 Å 647 between Phe 371 and the glycan are shown as dotted lines. (B) The contact between Arg 346 648 of the RBD and S309 light chain Asp 93 (PDB:7BEP). The electrostatic surface of S309 is 649 650 shown. (C) Cross-correlation matrix between pairs of antibodies. Each pairwise value is the correlation coefficient between the normalised log neutralisation titres of the corresponding 651 antibodies against a panel of SARS-CoV-2 (Victoria, Alpha, Beta, Gamma, Delta, BA.1). (D) 652

653 Cluster4X principal component analysis of the cross-correlation matrix in C from two
654 orthogonal views. (E) Principal component analysis on the sub-matrix of C consisting of only
655 the BA.1 antibodies.

Figure 5. Omicron antibody mapping and structures of Omicron/Fab complexes (A) 656 657 Mabscape antibody map (back and front views). Surface rendering of RBD (grey), ACE2 footprint in green, N343 glycan site in dark slate grey (marked with *). Spheres locate Omicron 658 659 antibodies: IGHV3-53, cyan, IGHV1-69, orange-red, the rest in yellow, in addition S309 is 660 shown dark blue,. (B) Heatmap of surface occupation of RBD by omicron antibodies (back and front views) by iron heat colours (black > blue > red > orange > yellow > white hot) according 661 662 to the relative level of antibody contact, calculated for each surface vertex as the number of antibodies within a 10 Å radius. BA.1 mutations are shown by the spikes. (C) Heatmap, as in 663 (B) but for the complete set of early pandemic response antibodies (Dejnirattisai et al., 2021a). 664 665 (D) as (C) but showing only potent neutralizing antibodies. (C) and (D) are redrawn from 666 (Dejnirattisai et al., 2022). (E) Superimposition based on the structures of the RBDs of 11 Omicron Fabs determined in complex with RBD or S (structure determination details in Table 667 S3). The RBD surface for the Omi-3 complex is shown in grey. Residues in the ACE2 footprint 668 and mutations associated with Omicron lineages are colored according to the key (as for Figure 669

1B). Fabs are are color-coded according to the site of interaction on the RBD. Front right shoulder binders in blue and back of the neck binders in red. Omi-2 and -12 are shown in magenta and Omi-9 in purple. The lower panel shows RBD alone orientated as in the upper panel. The four views correspond to successive 90° rotations about the vertical axis. See also Table S3A,B and Figures S2,S3

675

676 Figure 6. Structures of Omicron antibody complexes and correlation with sensitivity to 677 **RBD mutations** (A) Representation similar to **Figure 5E** with approximate front view. The 678 coloring scheme for RBD residues is shown in the key. Fab light chains (LC) are shown in blue 679 and heavy chains (HC) in red. Label coloring follows the antibody coloring in Figure 5E. (B) 680 IGHV3-53 adaptation. Front views of BA.1 RBD surface (BA.1 mutations in magenta) bound 681 to Omi-3 Fab (HC red, LC blue). Top panel superimposed on with early pandemic mAb 222 complex (mAb 222 in grey). The right panels show the contacts with Omicron mutations with 682 683 BA.1 RBD shown in green. The middle panel shows that the L3 loops pack differently against 684 R408 and D405 (mutated to Ser and Asn respectively in BA.2). In the right panel the H3 loop 685 (red) and its contact with 493 are compared. The next row of panels below is as above for Omi3 686 vs. Beta-27 (Liu et al., 2021b). Note a Tyr in Omi-3 instead of a Ser in Beta-27 at residue 33 makes stacking contacts with H505. The bottom row of panels is the corresponding images for 687 688 Omi-3 vs Omi-18. (C) Structural explanations for the relative sensitivity of Omi-9, -32 and -689 38 to mutations at spike residues 484 and 346. Note in Omi-9 the environment for residue 484 renders it sensitive to the E484K mutation found in Beta and Gamma, whilst Omi-32 and Omi-690 691 38 are knocked down and knocked out respectively by the mutation R346K. Omi-38 forms a 692 salt bridge with LC 50D and hydrophobic interactions with H3 Tyr 103. See also Figure S3 and S4. 693 694

Figure 7 BA.2 RBD structure and ACE2 affinity. (A) Residues 371-376 are seen in different
conformations and compared with those of BA.1 RBD (bright red). (B) Electrostatic surfaces
of the early pandemic, Delta, BA.1 and BA.2 RBDs. (C) Complex of ACE2 (green ribbons)

698 and BA.2 RBD (grey surface with Omicron mutations colored). (D) Differences of ACE2 and 699 BA.2 RBD interface with that of two previously reported ACE2/BA.1 RBD complexes (salmon 700 and blue, PDB IDs 7TN0 and 7WB (Han et al., 2022; McCallum et al., 2022)). (E) Orthogonal 701 views of the antigenic landscape for previous VoC and BA.1.1, BA.1 and BA.2, calculated 702 from pseudovirus neutralisation data. Distance between two positions is proportional to the 703 reduction in neutralisation titre when one of the corresponding strains is challenged with serum 704 derived by infection by the other. (F) Front right shoulder binding IGHV1-69 Omi-38 (HC red, 705 LC blue) contact with RBD R346 (grey). See also Table S3A,B.

706

Figure S1. mAb production and neutralization curves for BA.1, BA.1.1 and BA.2. (A)
Live virus neutralization of paired samples taken early and late following Omicron infection.
Geometric mean titres are shown above each column. The Wilcoxon matched-pairs signed rank
test was used for the analysis and two-tailed P values were calculated. (B) FRNT50 titres
against Victoria and Omicron BA.1 from donors for the production of Omicron mAb are
shown. (C) FACS plots showing the sorting of B cells using full length Omicron S. (D) early
pandemic mAb and (E) Beta mAb. Related to Figure 3.

714

715 Figure S2. Surface plasmon resonance measurements, Antigenic map calculation. (A-O) 716 SPR traces for the indicated BA.1 or BA.2 binding to the indicated mAb or ACE2. (P) 717 Neutralization data and model (log titre values) used to calculate antigenic maps in Figures 5 718 and 7E. Columns represent sera collected from inoculated volunteers or infected patients. Rows 719 are challenge strains: Victoria, Alpha, Delta, Beta, Gamma, BA.1, BA1.1 and BA.2 in order. 720 Values are colored according to their deviation from the reference value; the reference value is calculated on a serum-type basis as the average of neutralization titres from the row which 721 722 gives this the highest value, Related to Figure 5.

723

Figure S3. Summary structural analysis of Omicron elicited Fab complex structures.
Color coding matches that assigned to antibodies in Figure 5E. Related to Figures 5-7.

726

Figure S4. Antibody complex Structures. (A) Sensitivity of Omi-25 to K417N/T. K417 can 727 728 favourably interact with S31 and D50 in Victoria Alpha and Delta. (B) and (C) explain 729 sensitivity to the Delta L452R mutation, since this residue lies just underneath the H3 loop in 730 Oni-31 (B) and Omi-6 (C). The RBD is shown in green, the HS in red and LC in blue. (D) 731 Sensitivity of Omi-6 to BA.1.1 through specific LC and HC interactions with R346. (E) Omi-732 32 causes large conformational changes in the G446S loop of the BA.1 RBD (shown in green) 733 compared to the structure of the BA.1 RBD seen in the Omi-3 complex (grey). (F) pseudovirus 734 neutralization curves for selected IGHV1-58 mAb and control IGHV3-53 mAb 222 against Victoria and Iota (S477N). (G) The somatic mutation V53P contributes to re-folding of the H3 735 736 loop so that Q493R can be accommodated in Omi-12. (H) Somatic mutations in potent mAbs 737 belonging to the IGHV1-69 gene family. Mutations are mapped onto Omi-2 (which has the 738 longest H3 loop). Mutations are counted for the 6 antibodies listed in Table S1. Bound RBD is 739 shown in grey, the mAb light chain in blue and the heavy chain in dark grey with somatic 740 mutations colored according the frequency of changes from germline (dark grey to red to 741 yellow to white, according to the key shown). The H1-3 loops are shown semi-transparent with 742 a green outline. (I) cryo-EM maps for complexes of Omi-2, -38 and -42 with Beta S (shown in 743 grey), RBD in cyan and Fab in purple. The relevant FSC plots are shown alongside each 744 structure. The locally refined Omi-38 map is also shown, corresponding to the region boxed in 745 the global map. Related to Figures 5-7.

746

747 STAR Methods

748 **RESOURCE AVAILABILITY**

749 Lead Contact

750 Resources, reagents and further information requirement should be forwarded to and will be

responded by the Lead Contact, David I Stuart (dave@strubi.ox.ac.uk).

752

753 Materials Availability

Reagents generated in this study are available from the Lead Contact with a completed

755 Materials Transfer Agreement.

756

757 Data and Code Availability

The coordinates and structure factors of the crystallographic complexes are available from the PDB with accession codes listed in **Table S3**. Mabscape is available from https://github.com/helenginn/mabscape, <u>https://snapcraft.io/mabscape</u>. The data that support the findings of this study are available from the corresponding authors on request.

762 EXPERIMENTAL MODEL AND SUBJECT DETAILS

763

764 Study subjects

765 Monoclonal antibodies were isolated from individuals with sequence-confirmed Omicron infection in the early phase of the variant wave in late-2021. Following informed consent, 766 767 individuals with omicron were co-enrolled into the ISARIC/WHO Clinical Characterisation 768 Protocol for Severe Emerging Infections [Oxford REC C, reference 13/SC/0149] and the "Innate and adaptive immunity against SARS-CoV-2 in healthcare worker family and 769 770 household members" protocol affiliated to the Gastro-intestinal illness in Oxford: COVID sub 771 study [Sheffield REC, reference: 16/YH/0247] further approved by the University of Oxford 772 Central University Research Ethics Committee. Diagnosis was confirmed through reporting of

773 symptoms consistent with COVID-19 or a positive contact of a known Omicron case, and a 774 test positive for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) 775 from an upper respiratory tract (nose/throat) swab tested in accredited laboratories and lineage 776 sequence confirmed through national reference laboratories. A blood sample was taken following consent at least 14 days after PCR test confirmation. Clinical information including 777 778 severity of disease (mild, severe or critical infection according to recommendations from the 779 World Health Organisation) and times between symptom onset and sampling and age of 780 participant was captured for all individuals at the time of sampling.

781

782 Viral stocks

783 SARS-CoV-2/human/AUS/VIC01/2020(Caly et al., 2020), Alpha and Beta were provided by 784 Public Health England, Gamma cultured from a throat swab from Brazil, Delta was a gift from Wendy Barclay and Thushan de Silva, from the UK G2P genotype to phenotype consortium 785 and Omicron was grown from a positive throat swab (IRAS Project ID: 269573, Ethics Ref: 786 787 19/NW/0730. Briefly, VeroE6/TMPRSS2 cells (NIBSC) were maintained in Dulbecco's Modified Eagle Medium (DMEM) high glucose supplemented with 1% fetal bovine serum, 788 2mM Glutamax, 100 IU/ml penicillin-streptomycin and 2.5ug/ml amphotericin B, at 37 °C in 789 790 the presence of 5% CO2 before inoculation with 200ul of swab fluid. Cells were further 791 maintained at 37°C with daily observations for cytopathic effect (CPE). Virus containing 792 supernatant were clarified at 80% CPE by centrifugation at 3,000 r.p.m. at 4 °C before being 793 stored at -80 °C in single-use aliquots. Viral titres were determined by a focus-forming assay 794 on Vero CCL-81 cells (ATCC). Sequencing of the Omicron BA.1 isolate shows the expected 795 consensus S gene changes (A67V, \Delta69-70, T95I, G142D/\Delta143-145, \Delta211/L212I, ins214EPE, 796 G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, 797

798 N856K, Q954H, N969K, L981F), an intact furin cleavage site and a single additional mutation 799 A701V. Sequencing of the BA.1.1 isolate shows an additional mutation R346K and lack of mutation A701V compared with BA.1, and sequencing of BA.2 confirmed the expected 800 801 changes in the S gene (T19I, LPPA24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, 802 803 Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K). BA.1, BA.1.1 804 and BA.2 isolates have been fully sequenced and the deposited reads have INSDC accession 805 numbers ERR8959182, ERR9321875 and ERR9321876 respectively. Cells were infected with 806 the SARS-CoV-2 virus using an MOI of 0.0001.

807

Virus containing supernatant were harvested at 80% CPE and spun at 3000 rpm at 4 °C before
storage at -80 °C. Viral titres were determined by a focus-forming assay on Vero cells. Victoria
passage 5, Alpha passage 2 and Beta passage 4 stocks Gamma passage 1, Delta passage 3,
BA.1 passage 2, BA.1.1 passage 2, and BA.2 passage 2 were sequenced to verify that they
contained the expected spike protein sequence and no changes to the furin cleavage sites.

813

814 Bacterial Strains and Cell Culture

815 Vero (ATCC CCL-81) and VeroE6/TMPRSS2 cells were cultured at 37 °C in Dulbecco's Modified Eagle medium (DMEM) high glucose (Sigma-Aldrich) supplemented with 10% fetal 816 bovine serum (FBS), 2 mM GlutaMAX (Gibco, 35050061) and 100 U/ml of penicillin-817 818 streptomycin. HEK293T (ATCC CRL-11268) cells were passaged in DMEM high glucose 819 (Sigma-Aldrich) supplemented with 10% FBS, 1% 100X Mem Neaa (Gibco) and 1% 100X L-Glutamine (Gibco) at 37 °C with 5% CO₂. To express Wuhan RBD, beta-RBD and ACE2, 820 HEK293T cells were cultured in DMEM high glucose (Sigma) supplemented with 2% FBS, 821 1% 100X Mem Neaa and 1% 100X L-Glutamine at 37 °C for transfection. Spike and Human 822

823 mAbs were also expressed in HEK293T (ATCC CRL-11268) cells cultured in FreeStyle 293 824 Expression Medium (ThermoFisher, 12338018) at 37 °C with 5% CO₂. BA.1 and BA.2 RBDs 825 were expressed in Expi293FTM Cells (ThermoFisher), cultured in FreeStyleTM 293 Expression 826 Medium (ThermoFisher) at 30 °C with 8% CO₂. *E. coli DH5a* and Turbo Competent *E. coli* 827 (NEB) bacteria were used for transformation and large-scale preparation of plasmids. Single 828 colonies were picked and cultured in LB broth at 37 °C at 200 rpm in a shaker overnight.

829

830 Sera from Pfizer vaccinees

Pfizer vaccine serum was obtained from volunteers who had received either one or two doses 831 of the BNT162b2 vaccine. Vaccinees were Health Care Workers, based at Oxford University 832 833 Hospitals NHS Foundation Trust, not known to have prior infection with SARS-CoV-2 and 834 were enrolled in the OPTIC Study as part of the Oxford Translational Gastrointestinal Unit GI Biobank Study 16/YH/0247 [research ethics committee (REC) at Yorkshire & The Humber -835 836 Sheffield] which has been amended for this purpose on 8 June 2020. The study was conducted 837 according to the principles of the Declaration of Helsinki (2008) and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. Written 838 informed consent was obtained for all participants enrolled in the study. Participants were 839 840 studied after receiving two doses of, and were sampled approximately 28 days (range 25-38), 841 after receiving two doses of Pfizer/BioNtech BNT162b2 mRNA Vaccine, 30 micrograms, 842 administered intramuscularly after dilution (0.3 mL each), 17-28 days apart, then approximately 28 days (range 25-56) after receiving a third "booster dose of BNT162B2 vaccine. The mean 843 age of vaccinees was 37 years (range 22-66), 21 male and 35 female. 844

845

846 AstraZeneca-Oxford vaccine study procedures and sample processing

847 Full details of the randomized controlled trial of ChAdOx1 nCoV-19 (AZD1222), were previously published (PMID: 33220855/PMID: 32702298). These studies were registered at 848 849 ISRCTN (15281137 89951424) and ClinicalTrials.gov (NCT04324606 and and 850 NCT04400838). Written informed consent was obtained from all participants, and the trial is being done in accordance with the principles of the Declaration of Helsinki and Good Clinical 851 852 Practice. The studies were sponsored by the University of Oxford (Oxford, UK) and approval obtained from a national ethics committee (South Central Berkshire Research Ethics 853 Committee, reference 20/SC/0145 and 20/SC/0179) and a regulatory agency in the United 854 Kingdom (the Medicines and Healthcare Products Regulatory Agency). An independent DSMB 855 reviewed all interim safety reports. A copy of the protocols was included in previous 856 857 publications(Folegatti et al., 2020).

858

Data from vaccinated volunteers who received two or three doses: Vaccine doses were either 5 $\times 10^{10}$ viral particles (standard dose; SD/SD cohort n=21) or half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort n=4). The interval between first and second dose was in the range of 8-14 weeks. Blood samples were collected and serum separated on the day of vaccination and on pre-specified days after vaccination e.g. 14 and 28 days after boost.

865

866 Method Details

867 Isolation of Omicron S-specific single B cells by FACS

Omicron S-specific single B cell sorting was performed as previously described (Dejnirattisai
et al., 2021a). Briefly, PBMC were stained with LIVE/DEAD Fixable Aqua dye (Invitrogen)
followed by recombinant trimeric S-twin-Strep of BA.1. Cells were then incubated with CD3FITC, CD14-FITC, CD16-FITC, CD56-FITC, IgM-FITC, IgA-FITC, IgD-FITC, IgG-BV786

and CD19-BUV395, along with Strep-MAB-DY549 to stain the twin strep tag of the S protein. IgG+ memory B cells were gated as CD19+, IgG+, CD3-, CD14-, CD56-, CD16-, IgM-, IgAand IgD-, and S+ was further selected and single cells were sorted into 96-well PCR plates with 10 μ l of catching buffer (Tris, Nuclease free-H2O and RNase inhibitor). Plates were briefly centrifuged at 2000 xg for 1 min and left on dry ice before being stored at -80 °C.

877

878 Cloning and expression of Omicron S-specific human mAbs

879 Omicron S-specific human mAbs were cloned and expressed as described previously 880 (Dejnirattisai et al., 2021a). Briefly, genes for Ig IGHV, Ig V κ and Ig V λ were recovered from 881 positive wells by RT-PCR. Genes encoding Ig IGHV, Ig V κ and Ig V λ were then amplified 882 using Nested-PCR by a cocktail of primers specific to human IgG. PCR products of HC and LCs were ligated into the expression vectors of human IgG1 or immunoglobulin κ -chain or λ -883 chain by Gibson assembly (Gibson, 2011). For mAb expression, plasmids encoding HCs and 884 LCs were co-transfected by PEI-transfection into a HEK293T cell line, and supernatants 885 886 containing mAbs were collected and filtered 4-5 days after transfection, and the supernatants 887 were further characterized or purified.

888

889 ACE2 binding inhibition assay by ELISA

MAXISORP immunoplates were coated with 5 μ g/ml of purified ACE2-His protein overnight at 4 °C and then blocked by 2% BSA in PBS. Meanwhile, mAbs were serially diluted and mixed with 2.5 μ g/ml of recombinant BA.1 trimeric S-twin-Strep. Antibody-S protein mixtures were incubated at 37°C for 1 hr. After incubation, the mixtures were transferred into the ACE2-coated plates and incubated for 1 hr at 37 °C. After wash, StrepMAB-Classic (2-1507-001, iba) was diluted at 0.2 μ g/ml by 2% BSA and used as primary antibody followed by Goat anti-mouse IgG-AP (#A16093, Invitrogen) at 1:2000 dilution. The reaction was developed by adding

PNPP substrate and stopped with NaOH. The absorbance was measured at 405nm. The
ACE2/S binding inhibition was calculated by comparing to the antibody-free control well.
IC50 was determined using the Probit program from the SPSS package.

900

901 Focus Reduction Neutralization Assay (FRNT)

902 The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test (FRNT), where the reduction in the number of the infected foci is compared to a negative 903 904 control well without antibody. Briefly, serially diluted Ab or plasma was mixed with SARS-905 CoV-2 strains and incubated for 1 hr at 37 °C. The mixtures were then transferred to 96-906 well, cell culture-treated, flat-bottom microplates containing confluent Vero cell monolayers in 907 duplicate and incubated for a further 2 hrs followed by the addition of 1.5% semi-solid 908 carboxymethyl cellulose (CMC) overlay medium to each well to limit virus diffusion. A focus 909 forming assay was then performed by staining Vero cells with human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG (A0170; Sigma). Finally, the foci 910 911 (infected cells) approximately 100 per well in the absence of antibodies, were visualized by 912 adding TrueBlue Peroxidase Substrate. Virus-infected cell foci were counted on the classic AID 913 EliSpot reader using AID ELISpot software. The percentage of focus reduction was calculated 914 and IC₅₀ was determined using the probit program from the SPSS package.

915

916 Plasmid construction and pseudotyped lentiviral particles production

Pseudotyped lentivirus expressing SARS-CoV-2 S proteins were constructed as described
before (Nie et al., 2020, Liu et al., 2021), with some modifications. Compared to Wuhan
sequence, the gene sequences were designed to encode S protein of BA.1 (A67V, Δ69-70,
T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N,
N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K,

D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F), 922 BA.1.1 (BA.1 as above plus R346K), BA.2 (T19I, LPPA24S, G142D, V213G, G339D, S371F, 923 S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, 924 Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and 925 N969K. Briefly, synthetic codon-optimized SARS-CoV-2 BA.1 and BA.2 were custom 926 927 synthesized by GeneArt (Thermo Fisher Scientific GENEART). The insert fragments and pcDNA3.1 vector were cloned using Gibson assembly. The Victoria (S247R) construct is as 928 929 previously described in Liu et al., 2021.

930

931 R346K (R346K F То construct BA.1.1, mutagenic primers of 5'-932 GTGTTCAATGCCACCAAATTCGCCAGCGTGTAC-3' and R346K R 5'-GTACACGCTGGCGAATTTGGTGGCATTGAACAC-3') were PCR amplified by using 933 BA.1 construct as a template, together with two primers of pcDNA3.1 vector 934 5'-GGATCCATGTTCCTGCTGACCACCAAGAG-3' 935 (pcDNA3.1 BamHI F and 5'-GAATTCTCACTTCTCGAACTGAGGGTGGC-3'). 936 pcDNA3.1 Tag S EcoRI R 937 Amplified DNA fragments were purified by using QIAquick Gel Extraction Kit (QIAGEN) and joined with pcDNA3.1 vector followed by Gibson assembly. All constructs were verified 938 939 by Sanger sequencing after plasmid isolation using QIAGEN Miniprep kit (QIAGEN).

940

941 *Pseudoviral neutralization test*

The details of pseudoviral neutralization test were described previously (Liu et al., 2021) with some modifications. Briefly, neutralizing activity of potent monoclonal antibodies (mAbs) generated from donors who had recovered from Omicron- and Beta-infection as well as those who were infected during the early pandemic in UK were performed against Victoria, Omicron-BA.1, BA.1.1 and BA.2. A four-fold serial dilution of each mAb was incubated with

947	pseudoviral particles at 37°C, 5% CO2 for 1 hr. The stable HEK293T/17 cells expressing
948	human ACE2 were then added to the mixture at 1.5×10^4 cells/well. At 48 hr. post transduction,
949	culture supernatants were removed and 50 μ L of 1:2 Bright-GloTM Luciferase assay system
950	(Promega, USA) in 1x PBS was added to each well. The reaction was incubated at room
951	temperature for 5 mins and the firefly luciferase activity was measured using CLARIOstar®
952	(BMG Labtech, Ortenberg, Germany). The percentage of neutralization was calculated relative
953	to the control. Probit analysis was used to estimate the value of dilution that inhibits half of the
954	maximum pseudotyped lentivirus infection (PVNT50).

955

To determine the neutralizing activity of convalescent plasma/serum samples or vaccine sera,
3-fold serial dilutions of samples were incubated with the pseudoviral particles for 1 hr and the
same strategy as mAb was applied.

959

960 Antibody clustering on neutralization tests

Monoclonal antibodies isolated from patients during the early pandemic, Beta patients and
Omicron patients along with a panel of neutralization titres against Victoria, Alpha, Beta,
Gamma, Delta and Omicron-BA.1 pseudoviruses were clustered using cluster4x (Ginn, 2020).
Neutralization titres >10 mg/ul were given a fixed value of 100 mg/ul and all neutralization
values passed to cluster4x as log values.

966

967 *Antigenic landscape mapping*

Antigenic mapping was carried out as previously described (Dejnirattisai et al., 2022; Liu et al., 2021a). In short, each virus/vaccine was assigned a three-dimensional location. These were refined such that the distance between each virus (or vaccine) pair is proportional to the falloff in neutralization capacity when a patient is infected/inoculated with one of the pair and their

972 serum is challenged by the other. This used a panel of data derived from the following serum:
973 Victoria, Alpha, Beta, Gamma, Delta, Omicron, Chadox-vaccinated (2x, 3x) 28 days after
974 vaccination, Pfizer-vaccinated (2x, 3x) 28 days after vaccination. Neutralization titres were
975 carried out against Victoria, Alpha, Beta, Gamma, Delta, BA.1, BA1.1 and BA.2 pseudoviruses
976 (see Figure S2B for a full representation of collected data).

977

978 DNA manipulations

Cloning was done by using a restriction-free approach (Peleg and Unger, 2014). Mutagenic
megaprimers were PCR amplified (KAPA HiFi HotStart ReadyMix, Roche, Switzerland, cat.
KK3605), purified by using NucleoSpin® Gel and PCR Clean-up kit (Nacherey-Nagel,
Germany, REF 740609.50) and cloned into pJYDC1 (Adgene ID: 162458) (Zahradnik et al.,
2021). Parental pJYDC1 molecules were cleaved by DpnI treatment (1 h, NEB, USA, cat.
R0176) and the reaction mixture was electroporated into E.coli Cloni® 10G cells (Lucigen,
USA). The correctness of mutagenesis was verified by sequencing.

986

987 Cloning of Spike and RBD

988	Expression plasmids encoding Omicron spikes were constructed with human codon-optimized
989	sequences from BA.1 (EPI_ISL_6640917) and BA.2 (EPI_ISL_6795834.2). The constructs of
990	Wild-type and BA.1 Spike plasmids are the same as previously described (Dejnirattisai et al.,
991	2021a). The gene of BA.1 RBD (319-541) was amplified using primers (5'-
992	GCGTAGCTGAAACCGGCagagtgcagcctaccgagagc-3' and 5'-
993	gtcattcagCAAGCTttattagtgatggtgatggtgatgGAAATTCACGCACTTATTC-3'); BA.1 and
994	BA.2 RBD (330-532) was amplified using primers (5'-
995	GCGTAGCTGAAACCGGCcctaatatcaccaatctgtgc-3' and 5'-
996	gtcattcagCAAGCTttattagtgatggtgatggtgatgATTGGTGCTCTTCTTAGGGCC-3'); and the

gene fragments were cloned into the pOPOINTTGneo vector as previously described (Huo etal., 2021). The construct was verified by Sanger sequencing.

999

1000 Protein production

1001 Protein expression and purification were conducted largely as described previously 1002 (Dejnirattisai et al., 2021a; Zhou et al., 2021). Twin-strep tagged Omicron spike was transiently 1003 expressed in HEK293T cells and purified with Strep-Tactin XT resin (IBA lifesciences). 1004 Plasmids encoding BA.1 RBD (319-541), BA.1 RBD (330-532) and BA.2 RBD (330-532) 1005 were transiently expressed in Expi293F[™] Cells (ThermoFisher), cultured in FreeStyle[™] 293 1006 Expression Medium (ThermoFisher) at 30 °C with 8% CO2 for 4 days. BA.1 RBD (330-532) 1007 was expressed in the presence of 1 µg/mL kifunensine. The harvested medium was 1008 concentrated using a QuixStand benchtop system. His-tagged ACE2 and RBDs were purified 1009 with a 5 mL HisTrap nickel column (GE Healthcare), followed by a Superdex 75 10/300 GL 1010 gel filtration column (GE Healthcare).

1011

1012 IgG mAbs and Fab purification

Heavy and light chains of the indicated antibodies were transiently transfected into 293T cells. To purify full length IgG mAbs, supernatants of mAb expression were collected and filtered by a vacuum filter system and loaded on protein A/G beads over night at 4 °C. Beads were washed with PBS three times and 0.1 M glycine pH 2.7 was used to elute IgG. The eluate was neutralized with Tris-HCl pH 8 buffer to make the final pH=7. The IgG concentration was determined by spectrophotometry and buffered exchanged into PBS.

1019 Small amounts of Fab fragments were digested from purified IgGs with papain using a Pierce

1020 Fab Preparation Kit (Thermo Fisher), following the manufacturer's protocol. AstraZeneca and

1021 Regeneron antibodies were provided by AstraZeneca, Vir, Lilly and Adagio antibodies were1022 provided by Adagio.

1023

To express and purify large amount of Fabs, heavy chain and light chain expression plasmids
of each Fab were co-transfected into HEK293T cells by PEI. Cells were cultured for 5 days at
37°C with 5% CO2, culture supernatant was harvested and filtered using a 0.22 mm
polyethersulfone filter. Twin-strep tagged Fabs were purified using Strep-Tactin XT resin (IBA
lifesciences). IgG Omi-18, Omi-31 and Omi-42 were transiently expressed in Expi293FTM
Cells (ThermoFisher), cultured in FreeStyleTM 293 Expression Medium (ThermoFisher) at 30
°C with 8% CO2 for 5 days. Purification was performed in the same way as other IgGs.

1031

1032 Nanobody production

1033 The gene for nanobody C1 (NbC1) and F2 (NbF2) and were codon-optimized using the IDT 1034 Codon Optimization Tool, synthesized as a ready-to-clone gene fragment (Integrated DNA 1035 Technologies), and cloned into the phagemid vector pADL-23c. The nanobodies were 1036 produced as previously described (Huo et al., 2021). Briefly, the plasmid was transformed into the WK6 E. coli strain and protein expression induced by 1 mM IPTG grown overnight at 28 1037 1038 °C. Periplasmic extract was prepared by osmotic shock, and the nanobody protein was purified 1039 with a 5 mL HisTrap nickel column (Cytiva), followed by size exclusion with a Hiload 16/60 1040 Superdex 75 column.

1041

1042 Surface Plasmon Resonance

1043 The surface plasmon resonance experiments were performed using a Biacore T200 (GE
1044 Healthcare). All assays were performed with a running buffer of HBS-EP (Cytiva) at 25 °C.
1045 To determine the binding kinetics between the SARS-CoV-2 RBDs and ACE2 / monoclonal

1046 antibody (mAb), a Protein A sensor chip (Cytiva) was used. ACE2-Fc or mAb was 1047 immobilized onto the sample flow cell of the sensor chip. The reference flow cell was left 1048 blank. RBD was injected over the two flow cells at a range of five concentrations prepared by serial twofold dilutions, at a flow rate of 30 μ l min⁻¹ using a single-cycle kinetics programme. 1049 1050 Running buffer was also injected using the same programme for background subtraction. All 1051 data were fitted to a 1:1 binding model using Biacore T200 Evaluation Software 3.1. To 1052 determine the binding kinetics between the SARS-CoV-2 Spikes and ACE2, a Twin-Strep-1053 tag® Capture Kit (IBA-Lifesciences) was used. Spike protein containing a twin-Strep-tag was 1054 immobilized onto the sample flow cell of the sensor chip. The reference flow cell was left 1055 blank. ACE2 was injected over the two flow cells at a range of five concentrations prepared by serial twofold dilutions, at a flow rate of 30 μ l min⁻¹ using a single-cycle kinetics programme. 1056 1057 Running buffer was also injected using the same programme for background subtraction. All 1058 data were fitted to a 1:1 binding model using Biacore T200 Evaluation Software 3.1.

1059

1060 Competition assays of anti-Omicron BA.1 RBD mAbs

1061 Competition assays of anti-Omicron BA.1 RBD mAbs were performed on an Octet Red 96e 1062 machine (Sartorius) using Octet Anti-HIS (HIS2) Biosensors (Sartorius). His-tagged Omicron 1063 BA.2 RBD dissolved in the running buffer (10 mM HEPES, pH 7.4 and 150 mM NaCl) was 1064 used as the ligand and was first immobilized onto the biosensors. The biosensors were then 1065 washed with the running buffer to remove unbound RBD. Each biosensor was dipped into 1066 different saturating mAbs (Ab1) to saturate the bound RBD, except one biosensor was dipped 1067 into running buffer in this step, acting as the reference. Then all biosensors were washed with 1068 the running buffer again and dipped into wells containing the same competing antibody (Ab2). 1069 The y axis values of signals of different saturating antibodies in this step were divided by the

1070 value of the reference channel to get ratio results of different Ab1-Ab2 pairs. Ratio results close1071 to 0 indicated total competition while 1 indicated no competition.

1072

1073 Crystallization

1074 RBD proteins were deglycosylated with Endoglycosidase F1 before used for crystallization.
1075 Initial screening of crystals was set up in Crystalquick 96-well X plates (Greiner Bio-One) with
1076 a Cartesian Robot using the nanoliter sitting-drop vapor-diffusion method, with 100 nL of
1077 protein plus 100 nL of reservoir in each drop, as previously described (Walter et al., 2003).

1078 For crystallization, Omicron BA.1-RBD was mixed with Omi-25 Fab, and Omicron BA.2-1079 RBD was mixed with COVOX-150 and ACE2 separately, in a 1:1 molar ratio, with a final 1080 concentration of 13 mg ml⁻¹. Omicron BA.1-RBD was mixed with Omi-3 and EY6A Fabs, 1081 Omi-6 and COVOX-150 Fabs, Omi-9 Fab and Nanobody F2 (NbF2), and Omi-12 and beta-54 Fabs separately, in a 1:1:1 molar ratio, with a final concentration of 7 mg ml⁻¹. Omicron BA.1-1082 1083 RBD was mixed with Omi-32 Fab and NbC1 in a 1:1:1 molar ratio, with a final 1084 concentration of 11 mg/ml. Omi18 Fab, Omi31 Fab and NbC1 were mixed with 1085 Omicron BA.1-RBD and beta-RBD separately, in a 1:1:1:1 molar ratio, with a final concentration of 7 mg ml⁻¹. These complexes were separately incubated at room temperature 1086 1087 for 30 min. Omi-42 Fab was also crystallized.

1088

1089 Crystals of BA.1-RBD/Omi-25 were obtained from Molecular Dimensions Proplex condition 1090 1-31, containing 3.0 M Sodium formate and 0.1 M Tris pH 7.5. BA.2-RBD/COVOX-150 1091 crystals were obtained in 2 different space groups. Crystals of space group C2 were formed in 1092 Hampton Research PEGRx condition 1-29, containing 0.1 M Sodium citrate tribasic dihydrate 1093 pH 5.5 and 18% (w/v) PEG 3350. Crystals of space group P2₁ were obtained from Hampton 1094 Research PEGRx condition 1-19, containing 0.1 M Sodium acetate trihydrate pH 4.5 and 30%

1095 (w/v) PEG 1500. Crystals of BA.2-RBD/ACE2 were formed in Hampton Research PEGRx 1096 condition 1-23, containing 0.1 M MES monohydrate pH 6.0 and 20% (w/v) PEG monomethyl 1097 ether 2000 and further optimized in 0.09 M MES monohydrate pH 6.0 and 18% (w/v) PEG 1098 monomethyl ether 2000. Crystals of BA.1-RBD/Omi-3/EY6A were formed in Hampton 1099 Research PEGRx condition 1-25, containing 0.1 M sodium citrate tribasic dihydrate pH 5.0 and 30% (v/v) Jeffamine[®] ED-2001 pH 7.0. Crystals of BA.1-RBD/Omi-6/COVOX-150 were 1100 1101 obtained from Molecular Dimensions Proplex 1-23, containing 0.1 M Sodium HEPES pH 7.0 1102 and 15% (w/v) PEG 4000. Crystals of BA.1-RBD/Omi-9/NbF2 were obtained from Hampton 1103 Research PEGRx condition 1-19, containing 0.1 M Sodium acetate trihydrate pH 4.5 and 30% 1104 (w/v) PEG 1500. Crystals of BA.1-RBD/Omi-12/beta-54 were formed in Hampton Research 1105 PEGRx condition 1-46, containing 0.1 M Sodium citrate tribasic dihydrate pH 5.0 and 18% 1106 (w/v) PEG 20000. Complex of BA.1-RBD/Omi-12/beta-54 was screen in Hampton Research 1107 Ammonium sulphate screen C2, containing 2.4 M (NH4)₂SO4 and 0.1 M citric acid pH 5.0, 1108 but only crystals of Fab Omi-12 alone were formed in this condition. Crystals of BA.1-1109 RBD/Omi-32/NbC1 were formed in Hampton Research PEGRx condition 2-35, containing 1110 0.15 M Lithium sulfate monohydrate, 0.1 M Citric acid pH 3.5 and 18% (w/v) PEG 6000. 1111 Crystals of BA.1-RBD/Omi18/Omi31/NbC1 were formed in Molecular Dimensions Proplex 1112 condition 2-12, containing 0.2 M Ammonium sulfate, 0.1 M MES pH 6.5 and 20 % (w/v) PEG 1113 8000. Crystals of beta-RBD/Omi18/Omi31/NbC1 were formed in Molecular Dimensions 1114 JCSG plus condition 1-48, containing 0.04 M Potassium phosphate monobasic and 16% (w/v) 1115 PEG 8000. Crystals of Omi-42 Fab alone were formed in Hampton Research PEGRx condition 1116 1-24, containing 0.1 M Tris pH 8.0 and 30% (w/v) PEG monomethyl ether 2000. 1117

1118 *X-ray data collection, structure determination and refinement*

1119 Diffraction data were collected at 100 K at beamline I03 of Diamond Light Source, UK, apart 1120 from data of BA.1 RBD/Omi-18-Omi-31-C1 and Beta RBD/Omi-18-Omi-31-C1 complexes, 1121 which were collected at beamline I04. All data were collected as part of an automated queue 1122 system allowing unattended automated data collection (https://www.diamond.ac.uk/Instruments/Mx/I03/I03-Manual/Unattended-Data-1123 1124 Collections.html). Crystals were pre-frozen by mounting in loops and soaked for a second in cryo-protectant containing 25% glycerol and 75% mother liquor. Diffraction images of 0.1° 1125 1126 rotation were recorded on an Eiger2 XE 16M detector (exposure time from 0.015 to 0.026 s per image, beam size $80 \times 20 \,\mu\text{m}$, 10% beam transmission and wavelength of 0.9762 Å at I03; 1127 1128 exposure time 0.22 s per image, beam size $0.63 \times 50 \,\mu\text{m}$, 100% beam transmission and 1129 wavelength of 0.9795 Å at I04). Data were indexed, integrated and scaled with the automated 1130 data processing program Xia2-dials (Winter, 2010; Winter et al., 2018). 720° of data was collected from 2 positions of a single crystal for BA.1 RBD/Omi-18-Omi-31-C1 complex, and 1131 720° of data was collected for the P2₁ crystal form of the Omicron BA.2-RBD/COVOX-150 1132 1133 complex from two crystals. 360° of data was collected from a single crystal for each of the 1134 other data sets.

1135

1136 Structures were determined by molecular replacement with PHASER(McCoy et al., 2007). 1137 VhVl and ChCl domains which have the most sequence similarity to previously determined 1138 SARS-CoV-2 RBD/Fab structures (Dejnirattisai et al., 2021a; Dejnirattisai et al., 2021b; Huo 1139 et al., 2020; Liu et al., 2021a; Supasa et al., 2021; Zhou et al., 2021; Zhou et al., 2020) were 1140 used as search models for each of the current structure determination. Model rebuilding with 1141 COOT (Emsley et al., 2010) and refinement with Phenix (Liebschner et al., 2019) were used 1142 for all the structures. Due to the lower resolution, only rigid-body and group B-factor 1143 refinement were performed for structures of Omicron BA.1-RBD/Omi-6-150, BA.1-

1144 RBD/Omi-9-NbF2, BA.1-RBD/Omi-12-Beta-54 and BA.2-RBD/ACE2 complexes. Crystals 1145 of Omicron RBD complexes tend to diffract weakly and to lower resolution. The N- and C-1146 terminus of the RBD are flexible and have poor density. The ChCl domains in several 1147 complexes are also flexible with poorly defined density.

1148

Data collection and structure refinement statistics are given in **Table S3**. Structural comparisons used SHP (Stuart et al., 1979), residues forming the RBD/Fab interface were identified with PISA (Krissinel and Henrick, 2007) and figures were prepared with PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC).

1153

1154 Cryo-EM Grid Preparation

1155 A 3 μ L aliquot of B.1.135 S ectodomain at a concentration of ~1.2 μ m with fab (1:6 molar

1156 ratio) was prepared, aspirated and almost immediately applied to a freshly glow-discharged

1157 C-flat 200 mesh 2/1 grids at high intensity, 20 s, Plasma Cleaner PDC-002-CE, Harrick

1158 Plasma. Excess liquid was removed by blotting for 5 s with a force of -1 using vitrobot filter

1159 paper (grade 595, Ted Pella Inc.) at 4.5 °C, 100 % reported humidity before plunge freezing

1160 into liquid ethane using a Vitrobot Mark IV (Thermo Fisher). Fab/Spike complexes were

1161 incubated for 5-10 minutes prior to application to grids and plunge freezing.

1162

1163 Cryo-EM Data collection

1164 B.1.135 S ectodomain with Omi-2 fab. Movies were collected in mrc format using EPU on a

1165 200 kV Glacios microscope equipped with a Falcon-III detector in linear mode, a 50 µm

1166 aperture, and 100 µm objective were employed. A total of 3269 movies were recorded with a

1167 total dose of 45 e/Å2 and a pixel size 1.2 Å/pix with fringe free illumination..

1168 *B.1.135 S ectodomain with Omi-38 or Omi-42 fab.* Compressed tiff movies, 8084 and 5638 1169 respectively, each with 40 frames, were acquired on a Titan Krios (Thermo Fisher) operating 1170 at 300 kV with a K3 detector and 20 eV slit (Gatan) at a nominal magnification of 105 kX in 1171 super resolution mode (corresponding to a calibrated pixel size of 0.415 Å/pix at super 1172 resolution). A total dose of 50.5 e/Å² was applied to each movie and defocus range of 0.8-2.6 1173 μ m.

1174

1175 Cryo-EM Data Processing

For all three datasets, movies were 4-times binned and motion and ctf corrected on the fly 1176 1177 using the cryoSPARC v3.3.1 live framework (Punjani et al., 2017). Particles were initially 1178 picked with the blob-picker module before spike-like particles from 2D classification of this 1179 initial set were used as a template for template-based picking. Maps and FSC curves for all analyses are shown in Figure S4I. For Omi-42 particles were sorted in two rounds of 2D 1180 1181 classification followed by ab-initio reference classification into three classes, followed by a 1182 second classification into two classes. Particles from the best class, 106811 in total, were then further refined to 3.64 Å reported resolution (as determined within the cryoSPARC interface, 1183 1184 AuFSC = 0.143). A second, somewhat lower resolution class, where RBDs were oriented 1185 slightly differently was also refined (see Figure S4I). For Omi-2 182828 particles were 1186 derived from two rounds of classification, before further 3D classification and local 1187 refinement of the entire spike, but with the fulcrum focussed at the RBD/fab region to better 1188 resolve the interfaces of interest (various local refinements with masking and with/without 1189 subtracted densities failed to improve this region). For Omi-38, particles were sorted in two 1190 rounds of 2D classification before classification using three ab-initio models. The best class, 1191 with 201474 particles was then refined further, with global and local ctf refinement and no symmetry imposed, resulting in a final reported global reconstruction at AuFSC 0.143 of 2.90 1192

Å (as determined within the cryoSPARC interface (Punjani et al., 2017)). Local refinement of 1193 1194 Omi-38 with B.1.135 was performed also using cryoSPARC upon this particle set from 1195 which the areas outside of the area of interest (two upwards conformation RBDs in close 1196 proximity to each other and associated fabs) was subtracted. Areas were subtracted/refined 1197 using masks created in Chimera X (Pettersen et al., 2021). Masks were created as follows, 1198 within Chimera X, the area of interest was selected from the global spike map using the 1199 volume eraser tool, a gaussian filter was then applied, and the resulting volume imported into 1200 cryoSPARC with an additional dilation radius of 5 and soft padding width of 5 pixels. The 1201 final reconstruction from local refinement was reportedly at a resolution of AuFSC 0.143 1202 3.69 Å (as determined within the cryoSPARC interface) and clearly enhanced the variable 1203 domain/RBD interface.

1204

1205 Antibody mapping to RBD surface

1206 All Omicron antibodies and antibodies with previously solved structures (COVOX-45, -58, -1207 222, EY6A and beta-54) were used in a competition assay prepared for antibody mapping to 1208 the RBD surface. Antibody mapping was carried out using *mabscape* (Deinirattisai et al., 1209 2021a) and cluster4x (Ginn, 2020). Mid-point positions of EY6A, COVOX-45, COVOX-222 1210 and beta-54 were calculated from crystal structures and used to seed the analysis in 1000 Monte 1211 Carlo runs, whereas known structural positions of Omi-3, Omi-9, Omi-12 and COVOX-58 1212 were not included in the analysis and used as a cross-check. A total of 178 Monte Carlo runs 1213 formed a single cluster with the lowest score and these were used to calculate average positions 1214 for Omicron antibodies.

1215

1216 QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses are reported in the results and figure legends. Neutralization was measured
by FRNT. The percentage of focus reduction was calculated and IC₅₀ (FRNT50) was

	Journal Pre-proof			
1219	determined using the probit program from the SPSS package. The Wilcoxon matched-pairs			
1220	signed rank test was used for the analysis and two-tailed P values were calculated on geometric			
1221	mean values.			
1222				
1223	Video S1 Antibody response correlation clustering. Related to Figure 4D.			
1224	Video S2 Antigenic cartography three-dimensional analysis. Related to Figure 7E.			
1225				
1226				
1227	REFERENCES			
1228				
1229	Ai, J., Zhang, H., Zhang, Q., Zhang, Y., Lin, K., Fu, Z., Song, J., Zhao, Y., Fan, M., Wang,			
1230	H., et al. (2022). Recombinant protein subunit vaccine booster following two-dose			
1231	inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers			
1232	against SARS-CoV-2 and Variants of Concern. Cell Res 32, 103-106.			
1233				
1234	Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M.,			
1235	Pantano, E., Abbiento, V., Benincasa, L. <i>et al.</i> (2021) Hybrid immunity improves B cells and			
1236	antibodies against SARS-CoV-2 variants. Nature 600, 530–535.			
1230				
1238	Angyal, A., Longet, S., Moore, S.C., Payne, R.P., Harding, A., Tipton, T., Rongkard, P., Ali,			
1239	M., Hering, L.M., Meardon, N., <i>et al.</i> (2022). T-cell and antibody responses to first			
1240	BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care			
1241	workers: a multicentre prospective cohort study. Lancet Microbe 3, e21-e31.			
1242	workers, a mandelinie prospective conort study. Daneet wierobe 3, 621 est.			
1243	Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D.,			
1244	Spector, S.A., Rouphael, N., Creech, C.B., <i>et al.</i> (2021). Efficacy and Safety of the mRNA-			
1245	1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403-416.			
1246	1275 STIKS COV 2 Vaccine. IV Engl V Med 507, 105 110.			
1240	Caly, L., Druce, J., Roberts, J., Bond, K., Tran, T., Kostecki, R., Yoga, Y., Naughton, W.,			
1247	Taiaroa, G., Seemann, T., <i>et al.</i> (2020). Isolation and rapid sharing of the 2019 novel			
1249	coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia.			
1250	Med J Aust 212, 459-462.			
1250	Nicu J Must 212, 457 402.			
1251	Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E.,			
1252	Cromer, D., Scheepers, C., Amoako, D.G., <i>et al.</i> (2021). Omicron extensively but			
1255	incompletely escapes Pfizer BNT162b2 neutralization. Nature			
1255	https://doi.org/10.1038/s41586-021-04387-1.			
1256				
1257	Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E.R., Yu, J., Bahna,			
1258	F., Bimela, J., <i>et al.</i> (2021). Potent SARS-CoV-2 neutralizing antibodies directed against			
1259	spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819-833 e817.			
1260				

Chen, P., Nirula, A., Heller, B., Gottlieb, R.L., Boscia, J., Morris, J., Huhn, G., Cardona, J., 1261 1262 Mocherla, B., Stosor, V., et al. (2021). SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 384, 229-237. 1263 1264 1265 Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the 1266 1267 Spike protein of SARS-CoV-2. Science 369, 650-655. 1268 1269 Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., 1270 Cipolla, M., Mendoza, P., Agudelo, M. et al. (2021) Anti-SARS-CoV-2 receptor-binding 1271 domain antibody evolution after mRNA vaccination. Nature 600, 517–522. 1272 1273 Dejnirattisai, W., Huo, J., Zhou, D., Zahradnik, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E., 1274 Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., et al. (2022). SARS-CoV-2 Omicron-B.1.1.529 1275 leads to widespread escape from neutralizing antibody responses. Cell 185, 467-484 e415. 1276 Dejnirattisai, W., Zhou, D., Ginn, H.M., Duyvesteyn, H.M.E., Supasa, P., Case, J.B., Zhao, 1277 1278 Y., Walter, T.S., Mentzer, A.J., Liu, C., et al. (2021a). The antigenic anatomy of SARS-CoV-1279 2 receptor binding domain. Cell 184, 2183-2200 e2122. 1280 Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., 1281 1282 Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021b). Antibody evasion by the 1283 P.1 strain of SARS-CoV-2. Cell 184, 2939-2954 e2939. 1284 Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of 1285 1286 Coot. Acta Crystallographica Section D: Biological Crystallography 66, 486-501. 1287 1288 Folegatti, P.M., Ewer, K.J., Aley, P.K., Angus, B., Becker, S., Belij-Rammerstorfer, S., 1289 Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E.A., et al. (2020). Safety and 1290 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary 1291 report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467-478. 1292 1293 Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et 1294 al. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 1295 77-81. 1296 Gibson, D.G. (2011). Enzymatic assembly of overlapping DNA fragments. Methods 1297 1298 Enzymol 498, 349-361. 1299 1300 Ginn, H.M. (2020). Pre-clustering data sets using cluster4x improves the signal-to-noise ratio 1301 of high-throughput crystallography drug-screening analysis. Acta Crystallogr D Struct Biol 1302 76, 1134-1144. 1303 1304 Han, P., Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, P., Li, X., Peng, Q., Su, C., et al. 1305 (2022). Receptor binding and complex structures of human ACE2 to spike RBD from 1306 omicron and delta SARS-CoV-2. Cell 185, 630-640 e610. 1307 1308 Huo, J., Mikolajek, H., Le Bas, A., Clark, J.J., Sharma, P., Kipar, A., Dormon, J., Norman, 1309 C., Weckener, M., Clare, D.K., et al. (2021). A potent SARS-CoV-2 neutralising nanobody

- 1310 shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun 1311 12, 5469. 1312
- 1313 Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H.M.E., Ginn, H.M., Carrique, L.,
- Malinauskas, T., Ruza, R.R., Shah, P.N.M., et al. (2020). Neutralization of SARS-CoV-2 by 1314 Destruction of the Prefusion Spike. Cell Host Microbe 28, 445-454. 1315
- 1316
- 1317 Krissinel, E., and Henrick, K. (2007). Protein interfaces, surfaces and assemblies service 1318 PISA at European Bioinformatics Institute. J Mol Biol 372, 774-797.
- 1319
- 1320 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 1321 1322 receptor. Nature 581, 215-220.
- 1323
- 1324 Liebschner, D., Afonine, P.V., Baker, M.L., Bunkoczi, G., Chen, V.B., Croll, T.I., Hintze, B.,
- 1325 Hung, L.W., Jain, S., McCoy, A.J., et al. (2019). Macromolecular structure determination
- 1326 using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D
- 1327 Struct Biol 75, 861-877.
- 1328
- 1329 Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R.,
- 1330 Zhou, D., Mentzer, A.J., Zhao, Y., et al. (2021a). Reduced neutralization of SARS-CoV-2
- 1331 B.1.617 by vaccine and convalescent serum. Cell 184, 4220-4236 e4213.
- 1332
- 1333 Liu, C., Zhou, D., Nutalai, R., Duyvestyn, H., Tuekprakhon, A., Ginn, H., Dejnirattisai, W.,
- Supasa, P., Mentzer, A., Wang, B., et al. (2021b). The Beta mAb response underscores the 1334 1335 antigenic distance to other SARS-CoV-2
- 1336 variants. Cell, Host and Microbe 30, 53-68. 1337
- 1338 Mahase, E. (2021a). Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for 1339 preventing and reducing severe illness. BMJ 375, n2860.
- 1340
- 1341 Mahase, E. (2021b). Covid-19: Booster vaccine gives "significant increased protection" in over 50s. BMJ 375, n2814. 1342
- 1343
- 1344 McCallum, M., Czudnochowski, N., Rosen, L.E., Zepeda, S.K., Bowen, J.E., Walls, A.C.,
- 1345 Hauser, K., Joshi, A., Stewart, C., Dillen, J.R., et al. (2022). Structural basis of SARS-CoV-2
- 1346 Omicron immune evasion and receptor engagement. Science 375, 864-868.
- 1347 1348 McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read,
- 1349 R.J. (2007). Phaser crystallographic software. J Appl Crystallogr 40, 658-674.
- 1350
- Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Tanfous, T.B., DaSilva J., Bednarski E., 1351
- 1352 Ramos V., Zong S., Johnson B. et al. (2022). Increased Potency and Breadth of SARS-CoV-2
- 1353 Neutralizing Antibodies After a Third mRNA Vaccine Dose. bioRxiv
- 1354 https://doi.org/10.1101/2022.02.14.480394. 1355
- 1356 Nealon, J., and Cowling, B.J. (2022). Omicron severity: milder but not mild. Lancet 399, 412-413.
- 1357

1359	Peleg, Y., and Unger, T. (2014). Application of the Restriction-Free (RF) cloning for
1360	multicomponents assembly. Methods Mol Biol 1116, 73-87.
1361	
1362	Pettersen, E.F., Goddard, T.D., Huang, C.C., Meng, E.C., Couch, G.S., Croll, T.I., Morris,
1363	J.H. and Ferrin, T.E. (2021) UCSF ChimeraX: Structure visualization for researchers,
1364	educators, and developers. Protein Sci. 30, 70-82.
	educators, and developers. Protein Sci. 30, 70-82.
1365	
1366	Pinto, D., Park, Y.J., Beltramello, M., Walls, A.C., Tortorici, M.A., Bianchi, S., Jaconi, S.,
1367	Culap, K., Zatta, F., De Marco, A., et al. (2020). Cross-neutralization of SARS-CoV-2 by a
1368	human monoclonal SARS-CoV antibody. Nature 583, 290-295.
1369	
1370	Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L.,
1371	Perez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the
1372	BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603-2615.
1373	
1374	Punjani, A., Rubinstein, J., Fleet, D. and Brubaker, M.A. (2017). cryoSPARC: algorithms
1375	for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290–296.
1376	
1377	Rapp, M., Guo, Y., Reddem, E.R., Yu, J., Liu, L., Wang, P., Cerutti, G., Katsamba, P.,
1378	Bimela, J.S., Bahna, F.A., <i>et al.</i> (2021). Modular basis for potent SARS-CoV-2 neutralization
1378	by a prevalent IGHV1-2-derived antibody class. Cell Rep 35, 108950.
1379	by a prevalent for v 1-2-derived antibody class. Cen Rep 55, 108750.
1380	Pöltgen K. Nielsen S.C.A. Silve O. Vounes S.F. Zeslevsky, M. Costeles, C. Vong F.
	Röltgen, K., Nielsen, S.C.A., Silva, O., Younes, S.F., Zaslavsky, M., Costales, C., Yang, F.,
1382	Wirz, O.F., Solis, D., Hoh, R.A. <i>et al.</i> , (2022). Immune imprinting, breadth of variant
1383	recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
1384	Cell 185, 1025–1040.
1385	
1386	Stuart, D.I., Levine, M., Muirhead, H., and Stammers, D.K. (1979). Crystal structure of cat
1387	muscle pyruvate kinase at a resolution of 2.6 A. J Mol Biol 134, 109-142.
1388	
1389	Sun, Y., and Ho, M. (2020). Emerging antibody-based therapeutics against SARS-CoV-2
1390	during the global pandemic. Antib Ther 3, 246-256.
1391	
1392	Sun, Y., Wang, L., Feng, R., Wang, N., Wang, Y., Zhu, D., Xing, X., Yang, P., Zhang, Y.,
1393	Li, W., et al. (2021). Structure-based development of three- and four-antibody cocktails
1394	against SARS-CoV-2 via multiple mechanisms. Cell Res 31, 597-600.
1395	
1396	Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y.,
1397	Duyvesteyn, H.M.E., Nutalai, R., Tuekprakhon, A., et al. (2021). Reduced neutralization of
1398	SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201-2211 e2207.
1399	
1400	Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus,
1401	B., Baillie, V.L., Barnabas, S.L., Bhorat, Q.E., et al. (2021). Safety and efficacy of the
1402	ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
1403	randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99-111.
1404	,,
1405	Walls, A.C., Tortorici, M.A., Snijder, J., Xiong, X., Bosch, B.J., Rey, F.A., and Veesler, D.
1406	(2017). Tectonic conformational changes of a coronavirus spike glycoprotein promote
1407	membrane fusion. Proc Natl Acad Sci U S A <i>114</i> , 11157-11162.
1408	


1409 1410	Walter, T.S., Diprose, J., Brown, J., Pickford, M., Owens, R.J., Stuart, D.I., and Harlos, K. (2003). A procedure for setting up high-throughput nanolitre crystallization experiments. I.
1411 1412	Protocol design and validation. Journal of Applied Crystallography 36, 308-314.
1413	Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer-
1414	Babajew, D., Cipolla, M., Gaebler, C., Liberman, J.A. et al. (2021) mRNA vaccine-elicited
1415	antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622.
1416 1417	Weinreich, D.M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B.J.,
1417	Soo, Y., Rofail, D., Im, J., <i>et al.</i> (2021). REGN-COV2, a Neutralizing Antibody Cocktail, in
1419	Outpatients with Covid-19. N Engl J Med 384, 238-251.
1420	
1421	Winter, G. (2010). xia2: an expert system for macromolecular crystallography data reduction.
1422 1423	Journal of applied crystallography 43, 186-190.
1424	Winter, G., Waterman, D.G., Parkhurst, J.M., Brewster, A.S., Gildea, R.J., Gerstel, M.,
1425	Fuentes-Montero, L., Vollmar, M., Michels-Clark, T., Young, I.D., et al. (2018). DIALS:
1426	implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol
1427	74, 85-97.
1428 1429	Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M.,
1429	Zahradnik, J., and Shirakawa, K. (2022). Virological characteristics of SARS-CoV-2 BA.2
1431	variant bioXriv https://doi.org/10.1101/2022.02.14.480335.
1432	
1433	Yuan, M., Liu, H., Wu, N.C., Lee, C.D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y.,
1434	Tien, H., et al. (2020). Structural basis of a shared antibody response to SARS-CoV-2.
1435	Science 369, 1119-1123.
1436	
1437	Zahradnik, J., Dey, D., Marciano, S., Kolarova, L., Charendoff, C.I., Subtil, A., and
1438 1439	Schreiber, G. (2021). A Protein-Engineered, Enhanced Yeast Display Platform for Rapid
1439	Evolution of Challenging Targets. ACS Synth Biol.
1441	Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y.,
1442	Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of
1443	SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348-2361
1444	e2346.
1445	
1446	Zhou, D., Duyvesteyn, H.M.E., Chen, C.P., Huang, C.G., Chen, T.H., Shih, S.R., Lin, Y.C.,
1447	Cheng, C.Y., Cheng, S.H., Huang, Y.C., <i>et al.</i> (2020). Structural basis for the neutralization
1448 1449	of SARS-CoV-2 by an antibody from a convalescent patient. Nature structural & molecular biology 27, 950-958.
1450	biology 27, 750-756.
1451	Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu,
1452	R., <i>et al.</i> (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl
1453	J Med 382, 727-733.
1454	
1455	Zost, S.J., Gilchuk, P., Chen, R.E., Case, J.B., Reidy, J.X., Trivette, A., Nargi, R.S., Sutton,
1456	R.E., Siryadevara, N., Chen, E.C. <i>et al.</i> (2020a). Rapid isolation and profiling of a diverse
1457 1458	panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 26, 1422–1427.
140	11001 20, 1+22 - 1+27.


1459

- 1460 Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schafer, A.,
- 1461 Reidy, J.X., Trivette, A., Nargi, R.S., et al. (2020b). Potently neutralizing and protective
- 1462 human antibodies against SARS-CoV-2. Nature 584, 443-449.

1463

ournal pre-proof










Figure 2











Figure 5






Figure 7

- 1. Potent RBD antibodies from Omicron breakthrough vaccinees broadly neutralize VoC
- 2. These, possible recall antibodies, are focussed in two main clusters
- 3. Somatic maturation adapts public antibodies to recover potency
- 4. BA.2 > BA.1 ACE2 affinity. BA.2 < BA.1 neutralization by vaccine serum & Vir-S309

Analysis of antibodies from SARS-CoV-2 Omicron breakthrough infections reveals their structural and functional properties as well as ability to neutralize different pandemic strains.

building

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Fab	Dejnirattisai et al. 2021	N/A
lgG	Dejnirattisai et al. 2021 and Liu et al 2021	N/A
Human anti-NP (mAb 206)	Dejnirattisai et al. 2021	N/A
EY6A mAb	Zhou et al 2020	N/A
Regeneron mAbs	AstraZeneca	Cat#REGN10933, and REGN10987
AstraZeneca mAbs	AstraZeneca	Cat#AZD1061, AZD8895
Vir mAbs	Adagio	Cat#S309
Lilly mAbs	Adagio	Cat#Ly-CoV555, and Cat#Ly-CoV16
Adagio mAbs	Adagio	Cat#ADG10, Cat#ADG20, and Cat#ADG30
Anti-Human IgG (Fc specific)-Peroxidase	Sigma	Cat#A0170
Polyclonal Rabbit Anti-Goat Immunoglobulins/FITC	DAKO	Cat#F0250
Anti-c-Myc 9E10 antibody	Biolegend	Catt#626872
Anti-mouse IgG(Fc specific)-FITC antibody	Merck/Sigma Aldrich	Catt#F4143
Bacterial, Virus Strains, and Yeast		
SARS-CoV-2 (Australia/VIC01/2020)	Caly et al., 2020	N/A
SARS-CoV-2/Alpha	Public Health England	N/A
SARS-CoV-2/Beta	Public Health England	N/A
SARS-CoV-2/Gamma	Dejnirattisai et at., 2021	N/A
SARS-CoV-2/Delta	W. Barclay	Imperial College London
SARS-CoV-2/Omicron	This paper	N/A
SARS-CoV-2/B.1.525	Wendy Barclay and Thushan De Silva	N/A
DH5α bacteria	In Vitrogen	Cat#18263012
Saccharomyces cerevisiae EBY100	ATCC	Cat#MYA-4941
E. coli cloni 10G cells	Lucigen, USA	Cat#60117-1
DH5α bacteria	Invitrogen	Cat# 18263012
Biological Samples		
Serum from Pfizer-vaccinated individuals	University of Oxford	N/A
Serum from AstraZeneca-Oxford-vaccinated individuals	University of Oxford	N/A

PBMCs from SARS-CoV-2 patients	John Radcliffe Hospital in Oxford UK	N/A
Plasma from SARS-CoV-2 patients	John Radcliffe Hospital in Oxford UK, South Africa, and FIOCRUZ	N/A
	(WHO) Brazil	
Chemicals, Peptides, and Recombinant Proteins		
His-tagged SARS-CoV-2 RBD		
His-tagged SARS-CoV-2/Omicron RBD	This paper	N/A
His-tagged SARS-CoV-2 RBD-62	(Zahradnik et al., 2021b)	N/A
His-tagged SARS-CoV-2 RBD N501Y	Supasa et al. 2021	N/A
His-tagged SARS-CoV-2 RBD K417N, E484K, N501Y	Zhou et al. 2021	N/A
His-tagged SARS-CoV-2 RBD K417T, E484K, N501Y	Dejnirattisai et al. 2021b	N/A
His-tagged SARS-CoV-2 RBD L452R, T478K	Liu et al. 2021a	N/A
His-tagged human ACE2	Liu et al 2021	N/A
Human ACE2-hlgG1Fc	Liu et al. 2021r	N/A
His-tagged 3C protease	Libby et al. 1988	N/A
Phosphate buffered saline tablets	Sigma-Aldrich	Cat#P4417
Dulbecco's Modified Eagle Medium, high glucose	Sigma-Aldrich	Cat#D5796
Dulbecco's Modified Eagle Medium, low glucose	Sigma-Aldrich	Cat#D6046
FreeStyle™ 293 Expression Medium	Gibco	Cat#12338018
L-Glutamine–Penicillin–Streptomycin solution	Sigma-Aldrich	Cat#G1146
GlutaMAX [™] Supplement	Gibco	Cat#35050061
UltraDOMA PF Protein-free Medium	Lonza	Cat#12-727F
Opti-MEM™	Gibco	Cat#11058021
Fetal Bovine Serum	Gibco	Cat#12676029
Polyethylenimine, branched	Sigma-Aldrich	Cat#408727
Carboxymethyl cellulose	Sigma	Cat#C4888
Strep-Tactin [®] XT	IBA Lifesciences	Cat#2-1206-025
HEPES	Melford	Cat#34587-39108
Sodium Chloride	Honeywell	Cat#SZBF3340H
LB broth	Fisher Scientific UK	Cat#51577-51656
Mem Neaa (100X)	Gibco	Cat#2203945
Trypsin-EDTA	Gibco	Cat#2259288
TrypLE™ Express Enzyme	Gibco	Cat#12604013
L-Glutamine 200 mM (100X)	Gibco	Cat#2036885
SYPROorange (5000X in DMSO)	Thermo	Cat#S6651
Isopropyl β-d-1-thiogalactopyranoside	Meridian Bioscience	Cat#BIO-37036
Kanamycin	Melford	Cat#K22000
Lysozyme	Sigma-Aldrich	Cat#L6876
Tris-base	Melford	Cat#T60040
Imidazole	Sigma-Aldrich	Cat#56750

Cel	Э	ro	C	C
		I C	J	J

Triton-X-100	Sigma-Aldrich	Cat#8787
	-	
Turbonuclease	Sigma-Aldrich	Cat#T4330
RNAse A	Qiagen	Cat#158922
NaCl	Sigma-Aldrich	Cat#S9888
MgSO4	Sigma-Aldrich	Cat#746452
Na2HPO4	Melford	Cat#S23100
NaH2PO4	Melford	Cat#S23185
SD-CAA media	(Zahradnik et al., 2021a)	N/A
CF640-ACE2	(Zahradnik et al.,	N/A
HBS-EP+ Buffer 10×	2021b) Cytiva	Cat# BR100669
Regeneration Solution (glycine-HCl pH 1.7)	Cytiva	Cat# BR100838
Sensor Chip Protein A	Cytiva	Cat#29127555
His-tagged SARS-CoV-2 BA.1 variant RBD	This paper	N/A
His-tagged SARS-CoV-2 BA.2 variant RBD	This paper	N/A
SARS-CoV-2 BA.1 variant Spike	This paper	N/A
SARS-CoV-2 BA.2 variant Spike	This paper	N/A
Streptavidin-APC	Biolegend	Cat# 405207
Streptavidin-APC	Biolegend	Cat# 405207
RNase inhibitor	Promega	Cat# N2611
Protein G Plus/Protein A Agarose	Millipore	Cat#IP10
Pierce™ Fab Preparation Kit	Thermo Fisher	Cat#44985
Twin-Strep-tag [®] Capture Kit	IBA-Lifesciences	Cat# 2-4370-000
PEGRx 2	Hampton Research	HR2-084
ProPlex™ HT-96	Molecular Dimensions	MD1-42
JCSG-plus™ HT-96	Molecular Dimensions	MD1-40
Critical Commercial Assays		
Bright-Glo Luciferase Assay System	Promega	Cat# E2620
HIV Type 1 p24 Antigen ELISA 2.0	ZeptoMetrix	Cat# 0801002
Deposited Data		
Crystal structure of SARS-CoV-2 BA.1-RBD/Omi- 3 and EY6A Fab complex	This paper	PDB: 7ZF3
Crystal structure of SARS-CoV-2 BA.1-RBD/Omi- 9 Fab and NbF2 complex	This paper	PDB: 7ZF4
Crystal structure of SARS-CoV-2 BA.1-RBD/Omi- 12 and Beta-54 Fab complex	This paper	PDB: 7ZF5
Crystal structure of Omi-12 Fab	This paper	PDB: 7ZF6
Crystal structure of SARS-CoV-2 BA.2- RBD/ACE2 complex	This paper	PDB: 7ZF7
Crystal structure of SARS-CoV-2 BA.2- RBD/COVOX 150 Fab complex	This paper	PDB: 7ZF8 7ZF9


\sim		-	-	-
Ce	-	re	S	5
\sim	_		-	-

his paper	PDB: 7ZFB
his paper	PDB: 7ZFE
his paper	PDB: 7ZFC
his paper	PDB: 7ZFF
his paper	PDB: 7ZFD
his paper	EMD-14887, PDB:7ZR9
his paper	EMD-14910, PDB:7ZRC
his paper	EMD-14886, PDB: 7ZR8
his paper	EMD-14885, PDB: 7ZR7
N	
TCC	Cat#CRL-3022
TCC	Cat#CRL-3216
iibco,	Cat#A14527
TCC	Cat#CRL-11268™
TCC	Cat#CRL-11268
hermo Fisher	Cat#A29133
TCC	Cat#CCL-81
IIBSC	Ref. no. 100978
ricescu et al., 2006	N/A
ricescu et al., 2006	N/A
his paper	N/A
tewart SA et al. 2003	Addgene plasmid # 8454
lain Townsend	N/A
lettleship et al., 2008	, N/A
German Cancer	N/A
lesearch Center,	
German Cancer	N/A
lesearch Center, leidelberg, Germany	
	his paper his paper his paper his paper his paper his paper his paper his paper his paper his paper TCC TCC TCC TCC TCC TCC TCC TC


CellPress

Vector: human kappa light chain	German Cancer Research Center, Heidelberg, Germany (H. Wardemann	N/A
Vector: Human Fab	Univeristy of Oxford	N/A
Vector: pJYDC1	Adgene	ID: 162458
Vector: p8.91	di Genova et al., 2020	Nigel Temperton
Vector: pCSFLW	di Genova et al., 2020	Nigel Temperton
TM149 BirA pDisplay	University of Oxford, NDM (C. Siebold)	N/A
Software and Algorithms		
Software and Algorithms		https:///
СООТ	Emsley and Cowtan, 2004	https://www2.mrc- lmb.cam.ac.uk/personal /pemsley/coot/
Xia2-dials	Winter et al., 2018	https://xia2.github.io/p arameters.html
PHENIX	Liebschner et al., 2019	https://www.phenix- online.org/
PyMOL	Warren DeLano and Sarina Bromberg (2004)	https://pymol.org/
Data Acquisition Software 11.1.0.11	Fortebio	https://www.fortebio.c om/products/octet- systems-software
Data Analysis Software HT 11.1.0.25	Fortebio	https://www.fortebio.c om/products/octet-
Prism 9.0	GraphPad	systems-software <u>https://www.graphpad.</u> <u>com/scientific-</u> software/prism/
CryoSPARC v2.15.1-live	Structura Biotechnology Inc.	https://cryosparc.com/
SerialEM (version 3.8.0 beta)	https://bio3d.colorado. edu/SerialEM/; (Mastronarde, 2005)	N/A
EPU	Thermo Fisher	https://www.thermofishe r.com/uk/en/home/electr on- microscopy/products/sof tware-em-3d-vis/epu- software.html
IBM SPSS Software 27	IBM	https://www.ibm.com

mabscape	This paper	https://github.com/hele
		nginn/mabscape
		https://snapcraft.io/ma
		bscape
Biacore T200 Evaluation Software 3.1	Cytiva	www.cytivalifesciences.c
		om
Flowjo 10.7.1	BD	https://www.flowjo.com
SnapGene software 5.3.2	Insightful Science	www.snapgene.com
Other		
X-ray data were collected at beamline I03,	This paper	https://www.diamond.a
Diamond Light Source, under proposal ib27009		c.uk/covid-19/for-
for COVID-19 rapid access		scientists/rapid-
		access.html
TALON [®] Superflow Metal Affinity Resin	Clontech	Cat#635668
HiLoad [®] 16/600 Superdex [®] 200 pg	Cytiva	Cat#28-9893-35
Superdex 200 increase 10/300 GL column	Cytiva	Cat#28990944
HisTrap nickel HP 5-ml column	Cytiva	Cat#17524802
HiTrap Heparin HT 5-ml column	Cytiva	Cat#17040703
Amine Reactive Second-Generation (AR2G)	Fortebio	Cat#18-5092
Biosensors		
Octet RED96e	Fortebio	https://www.fortebio.c
		om/products/label-free-
		bli-detection/8-channel-
		octet-systems
Buffer exchange system "QuixStand"	GE Healthcare	Cat#56-4107-78
Cartesian dispensing system	Genomic solutions	Cat#MIC4000
Hydra-96	Robbins Scientific	Cat#Hydra-96
96-well crystallization plate	Greiner bio-one	Cat#E20113NN
Crystallization Imaging System	Formulatrix	Cat#RI-1000
Sonics vibra-cell vcx500 sonicator	VWR	Cat#432-0137
Cryo-EM data were collected at eBIC, Diamond,	This paper	https://www.diamond.ac.
under Proposal BI26983-2 for COVID-19 rapid		uk/covid-19/for-
access		scientists/rapid-
	T L'	access.html
Cryo-EM data were collected at OPIC, Division of	This paper	https://www.opic.ox.ac.u
Structural Biology, University of Oxford		k/
Biacore T200	Cytiva	https://www.cytivalifesci
		ences.com/en/us/shop/p
		rotein-analysis/spr-label-
		free-
		analysis/systems/biacor
QuivStand	GE Healthcare	e-t200-p-05644 Cat# 56-4107-78
QuixStand	GE mealinicale	Cal# 30-4107-70




Supplementary figure 1



Supplementary figure 2

mAb	Neutralization	Binding site	Structure features	Method / comments
Omi-6 (IGVH4-4)	Reduced on BA.1 and BA.2, seriously reduced on Delta and BA.1.1	Front of right shoulder	The L452R mutation in Delta will clash with CDR-H3. R346 makes potential salt bridges with D109 of CDR-H3 and D50 of CDR-L2. G56 and N58 of HC C" strand interact extensively with RBD Y449 and S446, respectively, which might not be as favourable in Omicron as Alpha, Beta or Gamma due to the G4465, G496S and Q498R mutations.	X-ray RBD/Fab complex. Low resolution, lack of detail.
Omi-31 (IGVH1.69)	Reduced on BA.2, seriously reduced on Delta	Front of right shoulder	L452R mutation in Delta will clash with CDR-H3. Q498R without the BA.1 and BA.1.1 specific mutations G446S and G496S may disturb the interactions of Y449 and G446 or G446S with HC C'' strand.	X-ray RBD/Fab complex.
Omi-32 (IGVH3-33)	Reduced on Alpha, Beta and Gamma, seriously reduced on BA.1.1 and BA.2	Front and top of right shoulder	Relative to Omi-6 and Omi-31, Omi-32 has a clockwise rotation of about 90° so that the LC is positioned on top of the right shoulder. The G446S loop, through a substantial conformation change interacts with H3 and H1. Q498R contacts L2. In Alpha, Beta and Gamma, the single mutation N501Y in the area may limit the conformation change required for binding. L452R in Delta could make a salt bridge to H3 D99, enhancing binding. G496S contacts L1, G446S contacts H1, and R346 interacts with H1, explaining the seriously reduced neutralization on BA.2 and BA.1.1.	X-ray RBD/Fab complex.
Omi-38 (IGVH1-69)	Reduced on BA.1 and BA.2, dead on BA.1.1	Front of right shoulder, positiond higher than Omi6	Extensive contacts from R346 to Y102 and D103 of H3, Y91 of L3, W32 of L1, and salt bridge with D50 of L2. G446 loop makes extensive interactions with L3, the carbonyl of S93 H-bonds to amino groups of V445 and G446. K444 salt bridges D103 of H3. The carbonyl of G446 H-bonds to N59 of LC C' strand. Short H3 (11 vs 21 residues in Omi31) does not contact L452.	Cryo-EM, spike- Fab complex.
Omi-9 (IGVH 3-30)	Reduced on Beta and Gamma	Left shoulder	R99 of H3 is in the vicinity of RBD residue 484, explaining the sensitivity to E484K in Beta and Gamma.	X-ray RBD/Fab complex. Low resolution, lack of details.
Omi-2 (IGVH1-69)	Good on all the VoC	Left shoulder	Binds similalrly to IGHV1-58 mAbs, differently to other IGHV1-69s of the current set. Omi-2 has a disulphide in H3 with first Cys at same position as that of Omi-12. The H3 Pro and Phe residues of IGHV1-58 which make ring stacking interaction with F486 of RBD are also conserved in Omi-2.	Cryo-EM, spike- Fab complex. Low resolution at interface, lack of details.
Omi-12 (IGVH1-58)	Equally good on all the VoC	Left shoulder	Has a disulphide and a glycosylation site in H3, binds at similar position to other IGHV1-58 mAbs, e.g. COVOX-253 and Beta-47. Contacts, but is not sensitive to S477N.	X-ray RBD/Fab complex. Low resolution, lack of details.
Omi-3 (IGVH3-53)	Equally good on all the VoC	Back of the neck	L1 is positioned similarly to Beta-27, with a Tyr at position 33 to be compatible with the N501Y and Y505H changes.	X-ray RBD/Fab complex.
Omi-18 (IGVH3-53)	Good on all the VoC	Back of the neck	L1 is one residue shorter than Omi-3 and less ordered in both Beta-RBD and BA.1-RBD complexes, so interactions with residues 501 and 505 are weak.	X-ray RBD/Fab complexes, determined with Beta and BA.1 RBD
Omi-25 (IGVH3-9)	Reduced on VoC carrying K417N/T mutation	Left shoulder	Main chain amide of N417 H-bonds to Y67 of LC DE-loop. K417 in Victoria, Alpha and Delta could H-bond to S31 of L1 or salt bridge to D50 of L2.	X-ray RBD/Fab complex.
Omi-42 (IGVH3-9)	good on all the VoC	Left shoulder	Main interactions are from H3 and H1 to the back of left shoulder. L1 contacts with D405 and R408. Neutralization of BA.2 is slightly affected by D405N and R408S mutations.	Cryo-EM, spike- Fab complex. Low resolution at interface, lack of detail.

Supplementary figure 3



Supplementary figure 4

Table S1. Omicron mAbs heavy and light chain variable gene usage and mutation analysis. Related to Figure 2.

		Heavy chain			Light chain				
mAbs	Patient No.	V-GENE	J-GENE	D-GENE	#Amino acid substitutions	K/λ	V-GENE	J-GENE	#Amino acid substitutions
Omi-02	07	1-69*01 , or 1-69D*01	2*01	2-21*02	7	К	3-20*01	5*01	5
Omi-03	07	3-53*01	4*02	1-26*01	5	К	3-20*01	2*01	0
Omi-06	07	4-4*07	3*02	3-16*02	4	К	1-39*01 , or 1D-39*01	4*01	12
Omi-08	07	1-46*01 , or 1-46*03	4*02	6-13*01	12	λ	1-40*02	1*01	4
Omi-09	07	3-30*01	3*02	4-17*01	6	λ	3-25*02	2*01 , or 3*01	4
Omi-12	08	1-58*02	3*02	2-2*01	12	К	3-20*01	1*01	9
Omi-16	09	3-66*02	4*02	2-15*01	9	К	3-20*01	2*01	7
Omi-17	09	3-66*02	4*02	6-19*01	7	К	3-20*01	2*01	6
Omi-18	09	3-53*01	6*02	4-11*01	11	λ	3-21*02	1*01	6
Omi-20	09	3-66*02	6*02	5-12*01	11	К	1-9*01	4*02	5
Omi-23	12	4-31*03	4*02	3-22*01	6	К	1-NL1*01	1*01	5
Omi-24	14	1-69*06	4*02	3-16*02	9	К	3-15*01	1*01	7
Omi-25	14	3-9*01	6*02	3-16*01	6	К	1-39*01, or 1D-39*01	2*01	7
Omi-26	14	1-18*01	4*02	1-26*01	12	λ	1-36*01	3*02	4
Omi-27	14	3-66*01, or 3-66*04	6*02	6-19*01	8	К	1-6*01	2*01	6
Omi-28	14	3-66*01 , or 3-66*04	4*02	3-16*01	4	К	3-20*01	1*01	9
Omi-29	14	3-53*04	6*02	2-15*01	11	λ	2-14*01 , or 2-14*03	3*02	6
Omi-30	14	1-69*06	6*02	2-15*01	10	λ	1-44*01	3*02	7
Omi-31	14	1-69*06	6*02	3-16*01	11	λ	1-44*01	3*02	6
Omi-32	08	3-33*01, or 3-33*06	4*02	2-21*02	6	К	3-20*01	4*01	6
Omi-33	08	3-33*01, or 3-33*06	4*02	2-21*02	10	к	3-20*01	4*01	4
Omi-34	09	1-69*06 , or 1-69*14	4*02	2-2*01	10	λ	1-40*01	1*01	6
Omi-35	09	3-9*01	6*02	2-2*02	5	λ	3-21*02	2*01 , or 3*01	7
Omi-36	09	3-66*02	4*02	2-15*01	9	К	3-20*01	2*01	5
Omi-38	15	1-69*09	3*01	1-26*01	16	К	1-5*01	5*01	10
Omi-39	07	3-43*01	6*03	2-2*01	8	К	4-1*01	3*01	6
Omi-41	08	1-18*04	4*02	3-9*01	11	К	4-1*01	2*02 ()	5
Omi-42	09	3-9*01	6*02	6-19*01	7	λ	2-8*01	2*01, or 3*01 or 3*02	5

Jour

Table S2A. VoC and Omicron neutralization data for Omicron mAbs. Related to Figure 3.

	Journal Pre-proof							
mAbs	Victoria	Alpha	Beta	Gamma	Delta	BA.1	BA.1.1	BA.2
Omi-02	0.015 ± 0.001	0.014 ± 0.005	0.009 ± 0.000	0.004 ± 0.000	0.014 ± 0.003	0.013 ± 0.001	0.015 ± 0.001	0.040 ± 0.021
Omi-03	0.007 ± 0.000	0.012 ± 0.007	0.009 ± 0.001	0.004 ± 0.000	0.004 ± 0.000	0.009 ± 0.002	0.015 ± 0.000	0.028 ± 0.002
Omi-06	0.007 ± 0.001	0.011 ± 0.002	0.012 ± 0.000	0.010 ± 0.003	5.040 ± 0.747	0.054 ± 0.005	1.505 ± 0.341	0.238 ± 0.007
Omi-08	0.014 ± 0.007	0.022 ± 0.002	0.007 ± 0.000	0.024 ± 0.007	0.048 ± 0.012	0.008 ± 0.004	0.007 ± 0.001	1.510 ± 0.683
Omi-09	0.004 ± 0.001	0.002 ± 0.000	1.218 ± 0.324	2.373 ± 1.008	0.008 ± 0.002	0.011 ± 0.005	0.017 ± 0.003	0.034 ± 0.010
Omi-12	0.005 ± 0.000	0.003 ± 0.001	0.006 ± 0.001	0.003 ± 0.000	0.003 ± 0.000	0.004 ± 0.001	0.009 ± 0.001	0.010 ± 0.001
Omi-16	0.016 ± 0.002	0.022 ±0.009	0.018 ±0.004	0.022 ±0.007	0.016 ±0.002	0.019 ±0.003	0.027 ± 0.007	0.067 ± 0.021
Omi-17	0.066 ± 0.015	0.098 ±0.027	0.021 ±0.007	0.021 ±0.007	0.074 ±0.019	0.028 ±0.005	0.026 ± 0.001	0.095 ± 0.008
Omi-18	0.041 ± 0.005	0.038 ±0.008	0.018 ±0.006	0.016 ±0.004	0.025 ±0.000	0.006 ±0.003	0.006 ± 0.001	0.007 ± 0.001
Omi-20	0.012 ± 0.002	0.023 ±0.004	0.019 ±0.009	0.019 ±0.006	0.008 ±0.001	0.043 ±0.012	0.032 ± 0.002	0.022 ± 0.005
Omi-23	0.005 ± 0.002	0.009 ±0.004	0.020 ±0.005	0.018 ±0.006	0.006 ±0.002	0.044 ±0.013	0.03 ± 0.001	0.028 ± 0.001
Omi-24	0.005 ± 0.001	0.008 ±0.003	0.006 ±0.001	0.010 ±0.005	>10	0.007 ±0.001	0.035 ± 0.010	0.008 ± 0002
Omi-25	0.003 ± 0.001	0.007 ±0.001	0.059 ±0.007	0.257 ±0.079	0.006 ±0.002	0.046 ±0.015	0.138 ± 0.046	0.056 ± 0.030
Omi-26	0.005 ± 0.000	0.010 ±0.003	0.055 ±0.020	0.214 ±0.046	0.005 ±0.001	0.034 ±0.000	0.055 ± 0.030	0.03 ± 0.011
Omi-27	0.026 ± 0.001	0.032 ±0.012	0.019 ±0.006	0.017 ±0.006	0.010 ±0.001	0.091 ±0.050	0.239 ± 0.052	0.039 ± 0.006
Omi-28	0.028 ± 0.004	0.028 ±0.001	0.019 ±0.010	0.033 ±0.008	0.018 ±0.002	0.032 ±0.009	0.075 ± 0.032	0.047 ± 0.010
Omi-29	0.044 ± 0.002	0.066 ±0.034	0.048 ±0.020	0.040 ±0.007	0.029 ±0.004	0.036 ±0.003	0.052 ± 0.004	0.192 ± 0.021
Omi-30	0.109 ± 0.035	0.043 ±0.016	0.028 ±0.009	0.038 ±0.004	>10	0.058 ±0.008	0.084 ± 0.021	0.045 ± 0.010
Omi-31	0.007 ± 0.001	0.020 ±0.003	0.011 ±0.005	0.017 ±0.006	>10	0.010 ±0.002	0.017 ± 0.009	0.083 ± 0.040
Omi-32	0.032 ± 0.016	0.102 ±0.041	0.460 ±0.092	0.430 ±0.012	0.012 ±0.002	0.024 ±0.011	4.642 ± 0.283	1.899 ± 0.280
Omi-33	0.028 ± 0.005	0.057 ± 0.017	0.136 ± 0.002	0.132 ± 0.037	0.011 ± 0.001	0.026 ± 0.008	0.113 ± 0.035	0.681 ± 0.0170
Omi-34	0.003 ± 0.001	0.041 ±0.027	0.003 ±0.000	0.008 ±0.002	>10	0.028 ±0.009	0.074 ± 0.016	0.014 ± 0.003
Omi-35	0.057 ± 0.003	0.080 ±0.030	0.128 ±0.058	0.136 ±0.024	0.280 ±0.059	0.069 ±0.032	0.262 ± 0.086	0.082 ± 0.043
Omi-36	0.056 ± 0.008	0.047 ± 0.009	0.018 ± 0.001	0.015 ± 0.000	0.026 ± 0.003	0.038 ± 0.006	0.053 ± 0.022	0.105 ± 0.023
Omi-38	0.001 ± 0.000	0.009 ± 0.001	0.004 ± 0.000	0.002 ± 0.000	0.004 ± 0.001	0.054 ± 0.028	>10	0.027 ± 0.001
Omi-39	0.015 ± 0.006	0.039 ± 0.007	0.009 ± 0.000	0.014 ± 0.001	0.012 ± 0.007	0.025 ± 0.004	>10	0.073 ± 0.014
Omi-41	0.090 ± 0.013	2.262 ± 1.199	>10	0.126 ± 0.059	>10	0.081 ± 0.004	0.191 ± 0.014	>10
Omi-42	0.016 ± 0.003	0.024 ± 0.001	0.011 ± 0.004	0.013 ± 0.003	0.019 ± 0.001	0.014 ± 0.002	0.017 ± 0.004	0.031 ± 0.008
REGN10987	0.032 ± 0.007	0.028 ± 0.003	0.007 ± 0.001	0.013 ± 0.002	0.017 ± 0.009	>10	>10	1.847 ± 1.231
REGN10933	0.004 ± 0.002	0.014 ± 0.002	3.284 ± 2.014	6.177 ± 1.914	0.003 ± 0.001	>10	>10	>10
AZD1061	0.013 ± 0.003	0.012 ± 0.002	0.014 ± 0.002	0.007 ± 0.002	0.038 ± 0.006	3.488 ± 2.085	>10	0.028 ± 0.014
AZD8895	0.005 ± 0.001	0.011 ± 0.002	0.046 ± 0.031	0.046 ± 0.016	0.003 ± 0.000	1.152 ± 0.170	6.078 ± 1.558	7.702 ± 2.224
AZD7442	0.009 ± 0.000	0.007 ± 0.001	0.012 ± 0.001	0.006 ± 0.003	0.005 ± 0.000	0.273 ± 0.062	3.816 ± 0.138	0.052 ± 0.004
ADG10	0.006 ± 0.000	0.010 ± 0.001	0.011 ± 0.001	0.003 ± 0.000	0.026 ± 0.005	>10	>10	>10
ADG20	0.004 ± 0.001	0.006 ± 0.000	0.01 ± 0.001	0.009 ± 0.000	0.006 ± 0.001	1.104 ± 0.509	1.269 ± 0.223	>10
ADG30	0.007 ± 0.002	0.016 ± 0.001	0.029 ± 0.003	0.002 ± 0.001	0.033 ± 0.007	>10	>10	>10
Ly-CoV-555	0.006 ± 0.002	0.009 ± 0.000	>10	>10	8.311 ± 4.059	>10	>10	>10
Ly-CoV16	0.034 ± 0.007	3.225 ± 1.030	>10	>10	0.012 ± 0.002	>10	>10	>10
S309	0.040 ± 0.005	0.078 ± 0.069	0.082 ± 0.002	0.076 ± 0.014	0.113 ± 0.028	0.256 ± 0.034	1.119 ± 0.119	5.035 ± 0.244

Table S2B. Neutralization data for early pandemic and Beta mAbs. Related to Figure 3.

Early pandomic mAbc	IC50 (ug/ml)					
Early pandemic mAbs	Victoria	BA.1	BA.1.1	BA.2		
40	0.006 ± 0.002	1.705 ± 0.840	0.544 ± 0.007	0.100 ± 0.007		
55	0.006 ± 0.002	>10	>10	>10		
58	0.019 ± 0.004	0.060 ± 0.041	0.876 ± 0.135	0.043 ± 0.007		
88	0.005 ± 0.002	>10	>10	>10		
132	0.012 ± 0.004	>10	>10	>10		
150	0.008 ± 0.004	>10	3.500 ± 0.712	>10		
158	0.021 ± 0.006	>10	2.843 ± 0.733	4.249 ± 0.694		
159	>10	>10	>10	>10		
165	0.007 ± 0.005	>10	>10	>10		
170	0.006 ± 0.001	>10	>10	>10		
175	0.012 ± 0.004	>10	>10	>10		
222	0.006 ± 0.000	0.021 ± 0.002	0.023 ± 0.001	0.249 ± 0.082		
253	0.021 ± 0.009	0.875 ± 0.373	0.415 ± 0.161	1.100 ± 0.049		
269	0.008 ± 0.004	>10	>10	>10		
278	0.001 ± 0.000	>10	>10	0.326 ± 0.011		
281	0.001 ± 0.000	>10	>10	>10		
316	0.001 ± 0.000	>10	>10	>10		
318	0.012 ± 0.003	9.490 ± 4.540	>10	0.303 ± 0.190		
384	0.001 ± 0.000	>10	>10	>10		
398	0.072 ± 0.065	>10	>10	>10		
253+55	0.001 ± 0.000	0.638 ± 0.315	0.451 ± 0.014	>10		
253+165	0.001 ± 0.000	>10	6.591 ± 0.799	>10		
			ug/ml)			
Beta mAbs	Beta	BA.1	BA.1.1	BA.2		
β06	0.005 ± 0.001	>10	>10	>10		
β10	0.021 ± 0.008	>10	>10	>10		
β20	0.006 ± 0.002	5.679 ± 0.452	1.836 ± 0.780	>10		
β22	0.041 ± 0.014	0.479 ± 0.029	0.130 ± 0.005	>10		
β23	0.005 ± 0.001	>10	>10	>10		
β24	0.002 ± 0.000	>10	>10	>10		
β26	0.004 ± 0.001	>10	>10	>10		
β27	0.003 ± 0.001	0.766 ± 0.043	0.274 ± 0.095	0.348 ± 0.030		
β29	0.009 ± 0.000	0.095 ± 0.029	0.066 ± 0.002	4.029 ± 0.402		
β30	0.002 ± 0.000	>10	>10	>10		
β32	0.023 ± 0.001	>10	>10	>10		
β33	0.020 ± 0.002	>10	>10	>10		
β34	0.030 ± 0.004	>10	>10	>10		
β38	0.004 ± 0.001	>10	>10	>10		
β40	0.001 ± 0.000	0.005 ± 0.001	0.002 ± 0.000	0.008 ± 0.002		
β43	0.014 ± 0.003	>10	>10	>10		
β44	0.008 ± 0.001	>10	>10	>10		
β45	0.010 ± 0.001	>10	>10	>10		
β47	0.002 ± 0.001	0.018 ± 0.009	0.011 ± 0.002	0.044 ± 0.006		
β48	0.002 ± 0.000	5.706 ± 0.676	0.011 ± 0.002 0.752 ± 0.052	5.042 ± 0.650		
β49	0.003 ± 0.001 0.014 ± 0.004	>10	>10	>10		
β50	0.014 ± 0.004 0.008 ± 0.001	>10	>10	>10		
β51	0.008 ± 0.001 0.003 ± 0.000	>10 >10	>10 >10	>10		
β53	0.007 ± 0.001	0.141 ± 0.026	5.849 ± 0.036	0.170 ± 0.073		
β54	0.002 ± 0.000	0.003 ± 0.001	0.001 ± 0.000	0.076 ± 0.029		
β55	0.009 ± 0.002	0.033 ± 0.008	0.009 ± 0.001	0.069 ± 0.008		

0.008

1.2

0.004

0.7

0.003

0.5

0.003

0.6

0.002

0.6

Omi42 Fab

63.8, 49.4, 72.3

90, 115.6, 90

65–2.32 (2.36-2.32) 0.182 (---)

0.078 (1.082)
 0.078 (1.082)

 8.0 (0.5)

 0.993 (0.348)

 92.6 (54.7)

 6.2 (3.7)

65-2.32 15619/865 0.231/0.269

3231

109

49

51

0.5

0.002

7ZFF

P21

Structure	BA.1 RBD/ Omi3-EY6A	BA.1 RBD/ Omi9-NbF2	BA.1 RBD/ Omi12- Beta54 ^a	Omi12 Fab ^a	BA.2 RBD/ ACE2	BA.2 RBD/150	BA.2 RBD/150	BA.1 RBD/ Omi6-150	BA.1 RBD/ Omi18-Omi31- NbC1	Beta RBD/ Omi18-Omi31- NbC1	BA.1 RBD/ Omi25	BA.1 RBD/ Omi-32-NbC1	
PDB ID	7ZF3	7ZF4	7ZF5	7ZF6	7ZF7	7ZF8	7ZF9	7ZFA	7ZFB	7ZFC	7ZFD	7ZFE	Г
Data collection													t
Space group	P212121	C2221	P21	C2221	P41212	C2	P21	<i>P</i> 1	P21	P3121	P43212	P21	t
Cell dimensions													T
<i>a</i> , <i>b</i> , <i>c</i> (A)	87.5, 119.9, 134.0	86.6, 205.1, 123.1	95.7, 156.3, 122.4	65.0, 210.1, 85.9	104.2, 104.2, 223.7	194.2, 94.9, 58.4	90.0, 83.9, 110.7	82.8, 114.8, 144.6	111.2, 135.1, 112.2	105.0, 105.0, 234.5	123.0, 123.0, 223.7	98.5, 159.9, 133.3	ſ
α,β,γ (°)	90, 90, 90	90, 90, 90	90, 90.3, 90	90, 90, 90	90, 90, 90	90, 101.0, 90	90, 102.0, 90	82.0, 80.6, 86.2	90, 101.7, 90	90, 90, 120	90, 90, 90	90, 106.9, 90	Γ
Resolution (Å)	73–3.15 (3.20-3.15) ^b	77–4.18 (4.25- 4.18)	78–5.50 (5.60- 5.50)	53-2.08 (2.12- 2.08)	76–3.46 (3.52- 3.46)	95–2.95 (3.00- 2.95)	66–3.25 (3.30- 3.25)	114–4.24 ((4.74- 4.24)	87–3.08 (3.13- 3.08)	85–3.24 (3.29- 3.24)	69–3.39 (3.45- 3.39)	81–3.25 (3.76- 3.25)	Γ
Rmerge	0.491 ()	0.728 ()	0.641 ()	0.179 ()	0.703 ()	0.490 ()	0.629 ()	0.330 ()	0.264 ()	0.265 ()	()	0.241 ()	Г
Rpim	0.136 (0.932)	0.207 (1.34)	0.259 (0.919)	0.052 (1.151)	0.138 (1.560)	0.198 (0.916)	0.173 (1.172)	0.205 (0.503)	0.073 (1.623)	0.073 (0.946)	0.233 (1.175)	0.097 (0.527)	Γ
I/ (I)	5.0 (0.6)	2.5 (0.4)	2.1 (0.4)	6.2 (0.2)	3.1 (0.3)	2.1 (0.3)	3.2 (0.4)	2.6 (1.6)	5.0 (0.2)	6.6 (0.3)	2.4 (0.4)	6.6 (1.6)	Г
CC1/2	0.955 (0.328)	0.877 (0.340)	0.849 (0.332)	0.994 (0.255)	0.992 (0.317)	0.939 (0.303)	0.971 (0.428)	0.918 (0.590)	0.997 (0.286)	0.995 (0.298)	0.967 (0.314)	0.995 (0.474)	Г
Completeness (%)	100 (99.2)	100 (98.3)	100 (98.2)	93.3 (62.9)	99.6 (99.3)	100 (99.8)	99.9 (97.9)	82.9 (74.8)	100 (100)	100 (98.4)	100 (99.7)	87.8 (49.0)	Γ
Redundancy	13.7 (14.2)	13.4 (13.1)	7.1 (7.4)	12.1 (6.8)	26.4 (27.8)	7.0 (6.7)	14.2 (14.7)	3.5 (3.5)	14.1 (13.5)	14.1 (14.3)	26.8 (28.3)	7.1 (7.0)	Γ
Refinement													Г
Resolution (A)	73–3.15	62-4.18°	78–5.50°	53-2.08	76–3.46°	57-2.95	62-3.25	114-4.24°	71-3.08	85-3.24	69–3.39	81-3.25	T
No. reflections	23771/1232	7769/415	11051/615	29710/1547	15216/802	18383/976	24438/1205	11920/595	50808/2718	23355/1202	23272/1216	26894/1395	Г
Rwork / Rfree	0.208/0.266	0.369/0.385	0.284/0.283	0.235/0.265	0.258/0.269	0.220/0.258	0.199/0.231	0.237/0.273	0.261/0.308	0.244/0.299	0.286/0.338	0.237/0.293	Г
Protein atoms #	8063	5757	16328	3320	6420	4798	9611	32080	17908	8914	9605	22831	Γ
Ligand/ion/water #	32			133	85		28						Γ
Protein B factors (A ²)	79	192	248	59	126	56	94	104	178	143	100	99	Γ
Ligand/ion/water B factors (A ²)	74			74	149		135						Γ

0.5

0.002

0.5

0.002

Tabl

0.008 1.0 * Omi12 is glycosylated at N102 of the heavy chain. ^b Values in parentheses are for highest-resolution shell. ^c Rigid body and group B-factor refinement only.

0.002

0.5

RMSD Bond length (Å)

RMSD Bond angles (°)

Table S3B. Cryo-EM data collection, refinement and validation statistics of spike/Fab complexes. Related to Figures 5-7.

0.010

0.7

0.6

0.002

	Omi-2/Beta Spike ectodomain	Omi-38/Beta Spike ectodomain	Omi-38/Beta Spike RBD (local refinement)	Omi-42/Beta Spike ectodomain
PDB ID / EMDB ID	7ZR9/EMD-14887	7ZRC, EMD-14910	7ZR8/EMD-14886	7ZR7/EMD-14885
Data collection and processing				
Microscope, Detector, Mode	Glacios, Falcon-III, linear	Krios, K3, superresolution	Krios, K3, superresolution	Krios, K3, superresolution
Voltage / kV	200	300	300	300
Electron exposure (e ⁻ /Å ²)	50.0	50.2	50.2	50.2
Defocus Range (um)	-1.5 to -3.5 [0.5]	-0.8 to -2.6 [0.3]	-0.8 to -2.6 [0.3]	-0.8 to -2.6 [0.3]
Nominal magnification kX	92	105	105	105
Pixel size [super res] (Å)	1.22	0.83	0.83	0.83
Symmetry imposed	C1	C1	C1	C1
Particles in final reconstruction	182,828	201,474	201,474	106,884
Map resolution in Å (4.0	2.9	3.7	3.6
FSC threshold	0.143	0.143	0.143	0.143
Refinement				
Initial model	7Q9G Spike, Alphafold Fab	7Q9G Spike Alphafold Fab	7Q9G Spike Alphafold Fab	7Q9G Spike Alphafold Fab
RBD conformation	Two-up, one poorly resolved, two clearly decorated.	Two mostly up, one tilted.	Two mostly up, one tilted, all decorated, but less clear for tilted.	Three-up, all decorated.
FSC threshold	0.143	0.143	0.143	0.143
Map sharpening B factor (Å ²)	-193	-69	-106	-95
Model non-hydrogen atoms	31014	30724	3693	30767
Protein residues	3899	3852	471	3878
Ligands	54	52	1	54
Protein mean B factor (Å ²)	238.1	30.3	31.2	213.7
Ligand mean B factor $(Å^2)$	130.9	42.9	21.8	167.6
RMSD Bond lengths (Å)	0.006	0.006	0.003	0.003
RMSD Bond angles (°)	0.857	0.596	0.458	0.496
Correlation Coefficient	0.76	0.75	0.82	0.79
Validation				
MolProbity score	1.76	1.61	1.65	1.58
Clashscore	8.11	7.36	7.02	6.01
Poor rotamers (%)	1.22	0.93	0.74	0.82
Ramachandran plot				
Favored (%)	96.2	96.7	96.1	96.3
Allowed (%)	3.69	3.3	3.9	3.7
Disallowed (%)	0.1	0.0	0.0	0.03

0.5

0.002